{
 "disease": "kidney-cancer",
 "label": "Kidney cancer",
 "url": "https://usebiotransfer.org/disease/kidney-cancer/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "b722fcb51f29",
  "targets": "ed55d171c60a"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "VHL",
   "ensembl": "ENSG00000134086",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "HIF1A",
   "ensembl": "ENSG00000100644",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "EPAS1",
   "ensembl": "ENSG00000116016",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "BELZUTIFAN": "APPROVAL"
   },
   "approved": [
    "BELZUTIFAN"
   ],
   "n_approved": 1,
   "approved_for": {
    "BELZUTIFAN": [
     "von Hippel-Lindau disease",
     "renal cell carcinoma",
     "hemangioblastoma",
     "pancreatic neuroendocrine tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "PBRM1",
   "ensembl": "ENSG00000163939",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "SETD2",
   "ensembl": "ENSG00000181555",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "BAP1",
   "ensembl": "ENSG00000163930",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KDM5C",
   "ensembl": "ENSG00000126012",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MTOR",
   "ensembl": "ENSG00000198793",
   "n_drug_entries": 26,
   "n_distinct_drugs": 25,
   "drugs": {
    "APITOLISIB": "PHASE_2",
    "AZD-8055": "PHASE_1_2",
    "BGT-226": "PHASE_1_2",
    "CC-115": "PHASE_2",
    "DACTOLISIB": "PHASE_3",
    "DS-3078A": "PHASE_1",
    "DS-7423": "PHASE_1",
    "GEDATOLISIB": "PHASE_3",
    "INDOXIMOD": "PHASE_2_3",
    "OMIPALISIB": "PHASE_1",
    "ONATASERTIB": "PHASE_2",
    "OSI-027": "PHASE_2",
    "PALOMID-529": "PHASE_1",
    "PANULISIB": "PHASE_1",
    "PERHEXILINE": "APPROVAL",
    "PF-04691502": "PHASE_2",
    "PKI-179": "PHASE_1",
    "RG-7603": "PHASE_1",
    "RIDAFOROLIMUS": "APPROVAL",
    "SAMOTOLISIB": "PHASE_2",
    "SAPANISERTIB": "PHASE_2",
    "SF-1126": "PHASE_2",
    "VISTUSERTIB": "PHASE_2",
    "VOXTALISIB": "PHASE_2",
    "VS-5584": "PHASE_1"
   },
   "approved": [
    "PERHEXILINE",
    "RIDAFOROLIMUS"
   ],
   "n_approved": 2,
   "approved_for": {
    "PERHEXILINE": [
     "cardiovascular disorder",
     "angina pectoris"
    ],
    "RIDAFOROLIMUS": []
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KDR",
   "ensembl": "ENSG00000128052",
   "n_drug_entries": 75,
   "n_distinct_drugs": 70,
   "drugs": {
    "4SC-203": "PHASE_1",
    "AEE-788": "PHASE_1_2",
    "ALACIZUMAB PEGOL": "PHASE_2",
    "ALTIRATINIB": "PHASE_1",
    "AXITINIB": "APPROVAL",
    "BFH-772": "PHASE_2",
    "BMS-690514": "PHASE_2",
    "BMS-817378": "PHASE_1",
    "BRIVANIB": "PHASE_3",
    "BRIVANIB ALANINATE": "PHASE_3",
    "CABOZANTINIB": "APPROVAL",
    "CABOZANTINIB S-MALATE": "APPROVAL",
    "CATEQUENTINIB": "PHASE_3",
    "CEDIRANIB": "APPROVAL",
    "CEP-11981": "PHASE_2",
    "CEP-5214": "UNKNOWN",
    "CM-082": "PHASE_2",
    "CYC-116": "PHASE_1",
    "DOVITINIB": "PHASE_3",
    "ENMD-2076": "PHASE_2",
    "ENMD-981693": "PHASE_2",
    "FAMITINIB": "PHASE_3",
    "FORETINIB": "PHASE_2",
    "FRUQUINTINIB": "APPROVAL",
    "GLESATINIB": "PHASE_2",
    "GOLVATINIB": "PHASE_1_2",
    "HENATINIB": "PHASE_1",
    "IBCASERTIB": "PHASE_3",
    "ILORASERTIB": "PHASE_2",
    "IMC-1C11": "PHASE_1",
    "JI-101": "PHASE_2",
    "KRN-633": "PHASE_1",
    "LENVATINIB": "APPROVAL",
    "LINIFANIB": "PHASE_3",
    "LUCITANIB": "PHASE_3",
    "MIDOSTAURIN": "APPROVAL",
    "MOTESANIB": "PHASE_3",
    "NINGETINIB": "PHASE_2",
    "NINTEDANIB": "APPROVAL",
    "NINTEDANIB ESYLATE": "APPROVAL",
    "OLINVACIMAB": "PHASE_2",
    "ORANTINIB": "PHASE_3",
    "OSI-632": "PHASE_2",
    "OSI-930": "PHASE_1",
    "PAZOPANIB": "APPROVAL",
    "PEGDINETANIB": "PHASE_2",
    "PF-00337210": "PHASE_1",
    "RAF-265": "PHASE_2",
    "RAMUCIRUMAB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "RG-1530": "PHASE_1",
    "RIVOCERANIB": "APPROVAL",
    "SEMAXANIB": "PHASE_3",
    "SORAFENIB": "APPROVAL",
    "SU-014813": "PHASE_2",
    "SUNITINIB": "APPROVAL",
    "SUNITINIB MALATE": "APPROVAL",
    "SURUFATINIB": "APPROVAL",
    "TAK-593": "PHASE_1",
    "TAS-115": "PHASE_1",
    "TELATINIB": "PHASE_2",
    "TELBERMIN": "PHASE_2",
    "TG100-801": "PHASE_2",
    "TIVOZANIB": "APPROVAL",
    "VANDETANIB": "APPROVAL",
    "VATALANIB": "PHASE_3",
    "X-82": "PHASE_2",
    "XL-820": "PHASE_2",
    "XL-999": "PHASE_2",
    "ZD-4190": "UNKNOWN"
   },
   "approved": [
    "AXITINIB",
    "CABOZANTINIB",
    "CABOZANTINIB S-MALATE",
    "CEDIRANIB",
    "FRUQUINTINIB",
    "LENVATINIB",
    "MIDOSTAURIN",
    "NINTEDANIB",
    "NINTEDANIB ESYLATE",
    "PAZOPANIB",
    "RAMUCIRUMAB",
    "REGORAFENIB",
    "RIVOCERANIB",
    "SORAFENIB",
    "SUNITINIB",
    "SUNITINIB MALATE",
    "SURUFATINIB",
    "TIVOZANIB",
    "VANDETANIB"
   ],
   "n_approved": 19,
   "approved_for": {
    "AXITINIB": [
     "renal cell carcinoma"
    ],
    "CABOZANTINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "hepatocellular carcinoma",
     "renal cell carcinoma",
     "medullary thyroid gland carcinoma"
    ],
    "CABOZANTINIB S-MALATE": [
     "thyroid gland carcinoma",
     "renal cell carcinoma"
    ],
    "CEDIRANIB": [],
    "FRUQUINTINIB": [
     "colorectal cancer",
     "colorectal neoplasm"
    ],
    "LENVATINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "renal cell carcinoma",
     "differentiated thyroid carcinoma",
     "thyroid gland carcinoma"
    ],
    "MIDOSTAURIN": [
     "mast cell leukemia",
     "mastocytosis",
     "acute myeloid leukemia by FAB classification",
     "systemic mastocytosis",
     "acute myeloid leukemia"
    ],
    "NINTEDANIB": [
     "idiopathic pulmonary fibrosis",
     "colorectal cancer",
     "interstitial lung disease",
     "systemic sclerosis",
     "pulmonary fibrosis"
    ],
    "NINTEDANIB ESYLATE": [
     "idiopathic pulmonary fibrosis",
     "systemic sclerosis",
     "non-small cell lung carcinoma",
     "Interstitial pneumonitis"
    ],
    "PAZOPANIB": [
     "soft tissue sarcoma",
     "renal cell carcinoma",
     "sarcoma"
    ],
    "RAMUCIRUMAB": [
     "gastric cancer",
     "non-small cell lung carcinoma",
     "gastric adenocarcinoma",
     "gastric neoplasm",
     "gastroesophageal junction adenocarcinoma"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "RIVOCERANIB": [
     "breast cancer"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "thyroid gland carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUNITINIB": [
     "gastrointestinal stromal tumor",
     "renal cell carcinoma",
     "neuroendocrine neoplasm"
    ],
    "SUNITINIB MALATE": [
     "renal cell carcinoma",
     "gastrointestinal stromal tumor",
     "neuroendocrine neoplasm"
    ],
    "SURUFATINIB": [],
    "TIVOZANIB": [
     "renal cell carcinoma"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "MET",
   "ensembl": "ENSG00000105976",
   "n_drug_entries": 38,
   "n_distinct_drugs": 36,
   "drugs": {
    "ALTIRATINIB": "PHASE_1",
    "AMG-208": "PHASE_2",
    "AMG-337": "PHASE_2",
    "AMIVANTAMAB": "APPROVAL",
    "AMUVATINIB": "PHASE_2",
    "ARRY-300": "PHASE_1",
    "BAFISONTAMAB": "PHASE_2",
    "BEPERMINOGENE PERPLASMID": "PHASE_3",
    "BMS-777607": "PHASE_1_2",
    "BMS-817378": "PHASE_1",
    "BPI-9016": "PHASE_1",
    "CABOZANTINIB": "APPROVAL",
    "CABOZANTINIB S-MALATE": "APPROVAL",
    "CAPMATINIB": "APPROVAL",
    "CRIZOTINIB": "APPROVAL",
    "EMD-1204831": "PHASE_1",
    "EMIBETUZUMAB": "PHASE_2",
    "FORETINIB": "PHASE_2",
    "GLESATINIB": "PHASE_2",
    "GOLVATINIB": "PHASE_1_2",
    "JNJ-38877605": "PHASE_1",
    "MERESTINIB": "PHASE_2",
    "MK-2461": "PHASE_1_2",
    "MK-8033": "PHASE_1",
    "NINGETINIB": "PHASE_2",
    "ONARTUZUMAB": "PHASE_3",
    "PF-04217903": "PHASE_1",
    "SAR-125844": "PHASE_2",
    "SAVOLITINIB": "PHASE_3",
    "SGX-523": "PHASE_1",
    "TAS-115": "PHASE_1",
    "TELISOTUZUMAB": "PHASE_1",
    "TELISOTUZUMAB VEDOTIN": "PHASE_3",
    "TEPOTINIB": "APPROVAL",
    "TEREVALEFIM": "PHASE_3",
    "TIVANTINIB": "PHASE_3"
   },
   "approved": [
    "AMIVANTAMAB",
    "CABOZANTINIB",
    "CABOZANTINIB S-MALATE",
    "CAPMATINIB",
    "CRIZOTINIB",
    "TEPOTINIB"
   ],
   "n_approved": 6,
   "approved_for": {
    "AMIVANTAMAB": [
     "non-small cell lung carcinoma"
    ],
    "CABOZANTINIB": [
     "thyroid cancer",
     "thyroid tumor",
     "hepatocellular carcinoma",
     "renal cell carcinoma",
     "medullary thyroid gland carcinoma"
    ],
    "CABOZANTINIB S-MALATE": [
     "thyroid gland carcinoma",
     "renal cell carcinoma"
    ],
    "CAPMATINIB": [
     "non-small cell lung carcinoma"
    ],
    "CRIZOTINIB": [
     "non-small cell lung carcinoma"
    ],
    "TEPOTINIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CD274",
   "ensembl": "ENSG00000120217",
   "n_drug_entries": 13,
   "n_distinct_drugs": 13,
   "drugs": {
    "ADEBRELIMAB": "PHASE_3",
    "ATEZOLIZUMAB": "APPROVAL",
    "AVELUMAB": "APPROVAL",
    "BINTRAFUSP ALFA": "PHASE_3",
    "COSIBELIMAB": "APPROVAL",
    "DANBURSTOTUG": "PHASE_2",
    "DURVALUMAB": "APPROVAL",
    "ENVAFOLIMAB": "PHASE_3",
    "ERFONRILIMAB": "PHASE_3",
    "INCB-086550": "PHASE_2",
    "PACMILIMAB": "PHASE_2",
    "SOCAZOLIMAB": "PHASE_3",
    "SUGEMALIMAB": "APPROVAL"
   },
   "approved": [
    "ATEZOLIZUMAB",
    "AVELUMAB",
    "COSIBELIMAB",
    "DURVALUMAB",
    "SUGEMALIMAB"
   ],
   "n_approved": 5,
   "approved_for": {
    "ATEZOLIZUMAB": [
     "urothelial carcinoma",
     "non-small cell lung carcinoma",
     "breast cancer",
     "small cell lung carcinoma",
     "breast neoplasm",
     "transitional cell carcinoma"
    ],
    "AVELUMAB": [
     "Merkel cell skin cancer",
     "urothelial carcinoma",
     "neuroendocrine neoplasm"
    ],
    "COSIBELIMAB": [
     "head and neck squamous cell carcinoma"
    ],
    "DURVALUMAB": [
     "non-small cell lung carcinoma",
     "small cell lung carcinoma",
     "urothelial carcinoma",
     "hepatocellular carcinoma"
    ],
    "SUGEMALIMAB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CA9",
   "ensembl": "ENSG00000107159",
   "n_drug_entries": 4,
   "n_distinct_drugs": 4,
   "drugs": {
    "ETHOXZOLAMIDE": "APPROVAL",
    "GIRENTUXIMAB": "PHASE_3",
    "IODINE I 124 GIRENTUXIMAB": "PHASE_2",
    "SULTHIAME": "APPROVAL"
   },
   "approved": [
    "ETHOXZOLAMIDE",
    "SULTHIAME"
   ],
   "n_approved": 2,
   "approved_for": {
    "ETHOXZOLAMIDE": [],
    "SULTHIAME": [
     "epilepsy"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "PD-1": {
    "n": 434,
    "n_observational": 38,
    "n_active": 203,
    "n_withdrawn": 13,
    "trials": [
     {
      "nct": "NCT03755739",
      "title": "Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03972657",
      "title": "A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03977571",
      "title": "Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04198766",
      "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04510597",
      "title": "Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605146",
      "title": "Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2024-10-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04724018",
      "title": "Sacituzumab Govitecan Plus EV in Metastatic UC",
      "status": "RECRUITING",
      "last_update": "2025-11-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04777994",
      "title": "Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04787042",
      "title": "Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067",
      "status": "RECRUITING",
      "last_update": "2024-11-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04895709",
      "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04977453",
      "title": "GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05048212",
      "title": "A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "status": "RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05155033",
      "title": "Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176483",
      "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263050",
      "title": "Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05269381",
      "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05319015",
      "title": "Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus",
      "status": "RECRUITING",
      "last_update": "2025-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327686",
      "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05329532",
      "title": "Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-09-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05361720",
      "title": "Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05614739",
      "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05656235",
      "title": "Renal Retention in High Grade Upper Tract Urothelial Cancer",
      "status": "RECRUITING",
      "last_update": "2026-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05663710",
      "title": "Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na\u00efve Patients With Advanced Clear Cell RCC",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05732831",
      "title": "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05733715",
      "title": "Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05738694",
      "title": "Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753839",
      "title": "The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial",
      "status": "RECRUITING",
      "last_update": "2023-06-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05756569",
      "title": "Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05768464",
      "title": "Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors",
      "status": "RECRUITING",
      "last_update": "2023-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05775471",
      "title": "Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05817903",
      "title": "Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients",
      "status": "RECRUITING",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05856981",
      "title": "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05888532",
      "title": "64Cu-GRIP B in Patients With Advanced Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05944237",
      "title": "HTL0039732 in Participants With Advanced Solid Tumours",
      "status": "RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05969496",
      "title": "Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05987241",
      "title": "Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06004336",
      "title": "A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06005818",
      "title": "Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)",
      "status": "RECRUITING",
      "last_update": "2025-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06053658",
      "title": "Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06211114",
      "title": "Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06255223",
      "title": "A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2025-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06265025",
      "title": "GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-03-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06265285",
      "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "status": "RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06270706",
      "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06281678",
      "title": "A Study of IBI363 in Subjects with Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2024-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06302569",
      "title": "Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364631",
      "title": "CARE1 Pragmatic Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2025-01-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06399419",
      "title": "CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2024-05-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06413680",
      "title": "A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body",
      "status": "RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06601296",
      "title": "Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06661720",
      "title": "Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06683846",
      "title": "Ivonescimab in the Treatment of Multiple Advanced Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764095",
      "title": "Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial",
      "status": "RECRUITING",
      "last_update": "2026-02-12",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06794229",
      "title": "Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06823427",
      "title": "9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06863311",
      "title": "Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06903312",
      "title": "Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06934057",
      "title": "Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-09-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06962787",
      "title": "A Study of BL-B01D1+TKI\u00b1Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06983210",
      "title": "Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07028125",
      "title": "Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07037004",
      "title": "Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery",
      "status": "RECRUITING",
      "last_update": "2026-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07049926",
      "title": "Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07087860",
      "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers",
      "status": "RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07115043",
      "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07125547",
      "title": "Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07128680",
      "title": "Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07166601",
      "title": "M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07175480",
      "title": "PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07187778",
      "title": "Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07187869",
      "title": "Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223424",
      "title": "Patient Preference for Subcutaneous vs. Intravenous Immune Therapy",
      "status": "RECRUITING",
      "last_update": "2026-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223541",
      "title": "Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07226544",
      "title": "Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227402",
      "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07383441",
      "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07401875",
      "title": "A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07410676",
      "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07489495",
      "title": "A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07489534",
      "title": "Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07510334",
      "title": "VSV-IFN\u03b2-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07555210",
      "title": "Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy",
      "status": "RECRUITING",
      "last_update": "2026-05-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07571551",
      "title": "Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07611825",
      "title": "Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07615348",
      "title": "CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623369",
      "title": "A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07634380",
      "title": "Sitagliptin With Pembro in RCC and Melanoma",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07749586",
      "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00441337",
      "title": "A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies",
      "status": "COMPLETED",
      "last_update": "2015-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00730639",
      "title": "A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-12-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01354431",
      "title": "BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2022-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01358721",
      "title": "Phase I Biomarker Study (BMS-936558)",
      "status": "COMPLETED",
      "last_update": "2021-10-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441765",
      "title": "PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine",
      "status": "TERMINATED",
      "last_update": "2017-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472081",
      "title": "Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",
      "status": "COMPLETED",
      "last_update": "2021-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01668784",
      "title": "Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)",
      "status": "COMPLETED",
      "last_update": "2022-08-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02014636",
      "title": "Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)",
      "status": "COMPLETED",
      "last_update": "2020-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02089685",
      "title": "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)",
      "status": "COMPLETED",
      "last_update": "2022-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02118337",
      "title": "A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02133742",
      "title": "A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2021-07-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02178722",
      "title": "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers",
      "status": "COMPLETED",
      "last_update": "2022-02-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02210117",
      "title": "Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02212730",
      "title": "A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)",
      "status": "TERMINATED",
      "last_update": "2020-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02231749",
      "title": "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02293980",
      "title": "A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02298959",
      "title": "Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02318771",
      "title": "Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02335918",
      "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02348008",
      "title": "Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:",
      "status": "COMPLETED",
      "last_update": "2022-09-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02419495",
      "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02423954",
      "title": "Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02432963",
      "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02437370",
      "title": "Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer",
      "status": "COMPLETED",
      "last_update": "2022-10-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02443324",
      "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02446860",
      "title": "A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)",
      "status": "TERMINATED",
      "last_update": "2025-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02460224",
      "title": "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",
      "status": "COMPLETED",
      "last_update": "2022-02-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02489695",
      "title": "Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02496208",
      "title": "Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02526017",
      "title": "Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2022-03-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02575222",
      "title": "Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-06-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02579811",
      "title": "Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2023-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02596035",
      "title": "An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-10-27",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02599324",
      "title": "Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors",
      "status": "COMPLETED",
      "last_update": "2023-11-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02599779",
      "title": "A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients",
      "status": "COMPLETED",
      "last_update": "2021-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02608268",
      "title": "Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02619253",
      "title": "Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02646748",
      "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02718066",
      "title": "Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02721732",
      "title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02763761",
      "title": "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo",
      "status": "WITHDRAWN",
      "last_update": "2018-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02771626",
      "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)",
      "status": "TERMINATED",
      "last_update": "2023-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02781506",
      "title": "Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02799095",
      "title": "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-05-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02811861",
      "title": "Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853331",
      "title": "Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)",
      "status": "COMPLETED",
      "last_update": "2026-02-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853344",
      "title": "Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)",
      "status": "COMPLETED",
      "last_update": "2023-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02855203",
      "title": "Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours",
      "status": "COMPLETED",
      "last_update": "2023-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867332",
      "title": "PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.",
      "status": "WITHDRAWN",
      "last_update": "2019-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02886897",
      "title": "A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2016-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02890069",
      "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",
      "status": "COMPLETED",
      "last_update": "2023-01-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02899078",
      "title": "Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02903914",
      "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02909452",
      "title": "Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02917772",
      "title": "Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02923531",
      "title": "Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-12-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02946671",
      "title": "Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2020-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02947165",
      "title": "Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.",
      "status": "COMPLETED",
      "last_update": "2022-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02952989",
      "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2019-07-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959554",
      "title": "Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control",
      "status": "TERMINATED",
      "last_update": "2021-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02960906",
      "title": "A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Na\u00efve Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02962804",
      "title": "Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2018-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02964078",
      "title": "Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02978404",
      "title": "Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2024-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02982954",
      "title": "A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02989714",
      "title": "Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2021-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02996110",
      "title": "A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03006887",
      "title": "Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03012581",
      "title": "Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types",
      "status": "COMPLETED",
      "last_update": "2024-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013335",
      "title": "Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen",
      "status": "COMPLETED",
      "last_update": "2021-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013946",
      "title": "Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy",
      "status": "TERMINATED",
      "last_update": "2025-02-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03015740",
      "title": "Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03024437",
      "title": "Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2025-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03050047",
      "title": "A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2018-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03050060",
      "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2022-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03055013",
      "title": "Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03065179",
      "title": "SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2021-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03086174",
      "title": "Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03111901",
      "title": "Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer",
      "status": "WITHDRAWN",
      "last_update": "2019-07-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03115801",
      "title": "A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers",
      "status": "TERMINATED",
      "last_update": "2021-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03117309",
      "title": "Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126331",
      "title": "Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136627",
      "title": "Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC",
      "status": "COMPLETED",
      "last_update": "2021-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03141177",
      "title": "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03142334",
      "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)",
      "status": "COMPLETED",
      "last_update": "2026-03-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03149822",
      "title": "Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03172754",
      "title": "Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03177239",
      "title": "Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)",
      "status": "UNKNOWN",
      "last_update": "2022-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03189186",
      "title": "Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas",
      "status": "WITHDRAWN",
      "last_update": "2021-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190174",
      "title": "Nivolumab (Opdivo\u00ae) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers",
      "status": "COMPLETED",
      "last_update": "2025-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03203473",
      "title": "Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03229278",
      "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-12-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03236935",
      "title": "Phase Ib of L-NMMA and Pembrolizumab",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03239145",
      "title": "Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
      "status": "COMPLETED",
      "last_update": "2026-07-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03244384",
      "title": "Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03260504",
      "title": "Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2025-12-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03260894",
      "title": "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)",
      "status": "COMPLETED",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03274258",
      "title": "Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277352",
      "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
      "status": "TERMINATED",
      "last_update": "2021-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03280667",
      "title": "Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03288545",
      "title": "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer",
      "status": "TERMINATED",
      "last_update": "2026-03-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03294083",
      "title": "A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03297593",
      "title": "Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03311334",
      "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-04-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03329950",
      "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03355976",
      "title": "BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "status": "TERMINATED",
      "last_update": "2023-03-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03444766",
      "title": "Study of Nivolumab for Advanced Cancers in India",
      "status": "COMPLETED",
      "last_update": "2020-12-04",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03454451",
      "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2023-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03463681",
      "title": "A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03469713",
      "title": "Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03474497",
      "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03502330",
      "title": "APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03511391",
      "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03540199",
      "title": "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03549000",
      "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.",
      "status": "TERMINATED",
      "last_update": "2024-12-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03562507",
      "title": "Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2024-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03589339",
      "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03606174",
      "title": "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03621982",
      "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-06-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03633110",
      "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
      "status": "COMPLETED",
      "last_update": "2022-04-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03637803",
      "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03647163",
      "title": "Ph I/II Trial of Systemic VSV-IFN\u03b2-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03655613",
      "title": "APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC",
      "status": "TERMINATED",
      "last_update": "2022-05-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03679767",
      "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",
      "status": "COMPLETED",
      "last_update": "2023-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03680521",
      "title": "Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-10-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693014",
      "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03729245",
      "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)",
      "status": "TERMINATED",
      "last_update": "2023-04-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03736330",
      "title": "A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-11-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03758781",
      "title": "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03775850",
      "title": "A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03793166",
      "title": "Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03809624",
      "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer",
      "status": "TERMINATED",
      "last_update": "2024-10-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03827837",
      "title": "Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors",
      "status": "UNKNOWN",
      "last_update": "2022-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03829111",
      "title": "CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03829436",
      "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2023-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849469",
      "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872947",
      "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03873402",
      "title": "A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03894618",
      "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
      "status": "COMPLETED",
      "last_update": "2025-04-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03927248",
      "title": "PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-05-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03935347",
      "title": "Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy",
      "status": "WITHDRAWN",
      "last_update": "2020-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03937219",
      "title": "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03945773",
      "title": "Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors",
      "status": "COMPLETED",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03987698",
      "title": "Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03991130",
      "title": "High Dose IL-2 in Combination With Anti-PD-1",
      "status": "TERMINATED",
      "last_update": "2026-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04040231",
      "title": "Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2025-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04060342",
      "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2022-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074967",
      "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04090710",
      "title": "SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04118855",
      "title": "Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04134182",
      "title": "Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.",
      "status": "UNKNOWN",
      "last_update": "2020-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04142931",
      "title": "Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2021-03-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04146831",
      "title": "Sintilimab in FH-deficient Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04148937",
      "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04152018",
      "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2025-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04163289",
      "title": "Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04187872",
      "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis",
      "status": "TERMINATED",
      "last_update": "2023-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04195750",
      "title": "A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04203901",
      "title": "Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04260802",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers",
      "status": "TERMINATED",
      "last_update": "2026-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04262375",
      "title": "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION",
      "status": "WITHDRAWN",
      "last_update": "2020-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04262427",
      "title": "The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2022-08-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04267120",
      "title": "Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)",
      "status": "TERMINATED",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04272034",
      "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04300140",
      "title": "Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-10-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04301011",
      "title": "Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04311710",
      "title": "A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types",
      "status": "TERMINATED",
      "last_update": "2023-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04322955",
      "title": "CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04339062",
      "title": "Cemiplimab in AlloSCT/SOT Recipients With CSCC",
      "status": "COMPLETED",
      "last_update": "2025-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04349267",
      "title": "Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370509",
      "title": "Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery",
      "status": "TERMINATED",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04374877",
      "title": "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04385654",
      "title": "Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04393350",
      "title": "Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04429321",
      "title": "Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary",
      "status": "TERMINATED",
      "last_update": "2024-04-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04434560",
      "title": "Neoadjuvant Immunotherapy in Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2022-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04483778",
      "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04485013",
      "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04495257",
      "title": "A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Na\u00efve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04513522",
      "title": "A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India",
      "status": "COMPLETED",
      "last_update": "2025-07-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04514484",
      "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04518046",
      "title": "Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522323",
      "title": "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04523272",
      "title": "A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04540705",
      "title": "A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread",
      "status": "COMPLETED",
      "last_update": "2024-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04544748",
      "title": "A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04561362",
      "title": "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04586231",
      "title": "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04606472",
      "title": "A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626479",
      "title": "Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626518",
      "title": "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04628780",
      "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04637594",
      "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644432",
      "title": "Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04691375",
      "title": "A Study of PY314 in Subjects With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-03-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04698213",
      "title": "Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04704219",
      "title": "Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04714697",
      "title": "Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736706",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04749602",
      "title": "Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.",
      "status": "COMPLETED",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04764487",
      "title": "A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line",
      "status": "UNKNOWN",
      "last_update": "2022-05-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04779151",
      "title": "Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab",
      "status": "TERMINATED",
      "last_update": "2025-12-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04802876",
      "title": "Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04810078",
      "title": "A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04848519",
      "title": "Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04895748",
      "title": "DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies",
      "status": "TERMINATED",
      "last_update": "2026-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04904302",
      "title": "Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2026-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913025",
      "title": "REduced Frequency ImmuNE Checkpoint Inhibition in Cancers",
      "status": "UNKNOWN",
      "last_update": "2022-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04913337",
      "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
      "status": "UNKNOWN",
      "last_update": "2024-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04953104",
      "title": "ARID1A and/or KDM6A Mutation and CXCL13 Expression",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955743",
      "title": "Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04958473",
      "title": "A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04987203",
      "title": "Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-05-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04995016",
      "title": "Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05012371",
      "title": "Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024318",
      "title": "NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05030506",
      "title": "A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05061537",
      "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-04-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05070247",
      "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-01-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05096390",
      "title": "Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC",
      "status": "UNKNOWN",
      "last_update": "2024-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05122546",
      "title": "CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05128487",
      "title": "A Study of NDI 1150-101 in Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05148546",
      "title": "Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05188118",
      "title": "Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-29",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215470",
      "title": "CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215574",
      "title": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05219318",
      "title": "Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05238883",
      "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239533",
      "title": "Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239728",
      "title": "A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256472",
      "title": "A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263609",
      "title": "Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib",
      "status": "WITHDRAWN",
      "last_update": "2022-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05293496",
      "title": "A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-10-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05302921",
      "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05347212",
      "title": "Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05354102",
      "title": "A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128",
      "status": "UNKNOWN",
      "last_update": "2024-05-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05363631",
      "title": "Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05397093",
      "title": "ITIL-306 in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-04-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05407441",
      "title": "Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05485896",
      "title": "Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05487859",
      "title": "Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05501054",
      "title": "Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05544929",
      "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05567588",
      "title": "Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05578664",
      "title": "Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-08-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05581004",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585034",
      "title": "Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb\u00ae808 in Combination With Pembrolizumab in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05597839",
      "title": "Study of DF9001 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-10-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05614102",
      "title": "A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05653882",
      "title": "A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05661955",
      "title": "A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05678673",
      "title": "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05704985",
      "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05708950",
      "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)",
      "status": "COMPLETED",
      "last_update": "2026-06-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05714553",
      "title": "NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours",
      "status": "TERMINATED",
      "last_update": "2026-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05788484",
      "title": "A Study of CDX-585 in Patients With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-06-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05789069",
      "title": "A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05805501",
      "title": "A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05808608",
      "title": "A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05816642",
      "title": "Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05846646",
      "title": "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC",
      "status": "TERMINATED",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05858736",
      "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05877820",
      "title": "A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC",
      "status": "COMPLETED",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05899049",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05928806",
      "title": "Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial",
      "status": "SUSPENDED",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05935748",
      "title": "Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)",
      "status": "TERMINATED",
      "last_update": "2025-11-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05961111",
      "title": "A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-07-27",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06034860",
      "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types",
      "status": "TERMINATED",
      "last_update": "2024-11-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06035224",
      "title": "Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06049576",
      "title": "Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06099782",
      "title": "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06108479",
      "title": "Study of DF6215 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06114940",
      "title": "Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)",
      "status": "TERMINATED",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06146777",
      "title": "Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-11-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06191796",
      "title": "Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)",
      "status": "TERMINATED",
      "last_update": "2025-06-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06284564",
      "title": "A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06285097",
      "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06307431",
      "title": "A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06361810",
      "title": "PSMA Therapy and Immunotherapy in Kidney Cancer",
      "status": "WITHDRAWN",
      "last_update": "2025-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06472895",
      "title": "A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06523049",
      "title": "Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "status": "TERMINATED",
      "last_update": "2026-02-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06580938",
      "title": "A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer",
      "status": "TERMINATED",
      "last_update": "2026-03-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06584435",
      "title": "A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06708949",
      "title": "A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06716853",
      "title": "A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-02-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860386",
      "title": "Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC",
      "status": "SUSPENDED",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06884683",
      "title": "Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2025-03-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06894771",
      "title": "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)",
      "status": "COMPLETED",
      "last_update": "2026-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06976021",
      "title": "Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07000149",
      "title": "A Study to Investigate the Efficacy and Safety of Volrustomig \u00b1 Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07011849",
      "title": "Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases",
      "status": "WITHDRAWN",
      "last_update": "2025-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07160335",
      "title": "A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda\u00ae in Multiple Resected Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07233668",
      "title": "Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07338981",
      "title": "The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07460206",
      "title": "Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07470840",
      "title": "SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07488533",
      "title": "Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07488572",
      "title": "Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07494435",
      "title": "Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07576725",
      "title": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07593040",
      "title": "Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07620574",
      "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07667335",
      "title": "Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07686744",
      "title": "Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07689240",
      "title": "Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691476",
      "title": "A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07715565",
      "title": "Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07741617",
      "title": "A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 10,
     "n_observational": 0,
     "n_active": 3,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT07410676",
       "title": "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 \u00b1 Pembrolizumab in Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-02-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07489534",
       "title": "Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction",
       "status": "RECRUITING",
       "last_update": "2026-03-24",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02867332",
       "title": "PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.",
       "status": "WITHDRAWN",
       "last_update": "2019-03-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02983045",
       "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2023-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03435640",
       "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
       "status": "TERMINATED",
       "last_update": "2023-03-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03729245",
       "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)",
       "status": "TERMINATED",
       "last_update": "2023-04-11",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03935347",
       "title": "Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy",
       "status": "WITHDRAWN",
       "last_update": "2020-01-02",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04483778",
       "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-04-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04540705",
       "title": "A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread",
       "status": "COMPLETED",
       "last_update": "2024-02-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05935748",
       "title": "Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)",
       "status": "TERMINATED",
       "last_update": "2025-11-12",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "nivolumab",
     "pembrolizumab"
    ]
   },
   "CTLA-4": {
    "n": 127,
    "n_observational": 14,
    "n_active": 69,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT03755739",
      "title": "Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03977571",
      "title": "Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04605146",
      "title": "Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2024-10-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05048212",
      "title": "A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176483",
      "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327686",
      "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05361720",
      "title": "Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05536141",
      "title": "A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753839",
      "title": "The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial",
      "status": "RECRUITING",
      "last_update": "2023-06-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05817903",
      "title": "Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients",
      "status": "RECRUITING",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05824975",
      "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)",
      "status": "RECRUITING",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05888532",
      "title": "64Cu-GRIP B in Patients With Advanced Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364631",
      "title": "CARE1 Pragmatic Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2025-01-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06399419",
      "title": "CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2024-05-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06866262",
      "title": "Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06903312",
      "title": "Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07128680",
      "title": "Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07188896",
      "title": "A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07195682",
      "title": "A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227415",
      "title": "Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07293351",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07383441",
      "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07401875",
      "title": "A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07510334",
      "title": "VSV-IFN\u03b2-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07516366",
      "title": "Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07611825",
      "title": "Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623369",
      "title": "A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00057889",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00378482",
      "title": "A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01445379",
      "title": "Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer",
      "status": "COMPLETED",
      "last_update": "2019-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472081",
      "title": "Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",
      "status": "COMPLETED",
      "last_update": "2021-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02089685",
      "title": "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)",
      "status": "COMPLETED",
      "last_update": "2022-09-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02210117",
      "title": "Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02231749",
      "title": "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02419495",
      "title": "Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02496208",
      "title": "Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626130",
      "title": "Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-07-07",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02762006",
      "title": "Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02763761",
      "title": "An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo",
      "status": "WITHDRAWN",
      "last_update": "2018-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02771626",
      "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)",
      "status": "TERMINATED",
      "last_update": "2023-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02812420",
      "title": "Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02917772",
      "title": "Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02950766",
      "title": "NeoVax Plus Ipilimumab in Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02960906",
      "title": "A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Na\u00efve Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02982954",
      "title": "A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2022-11-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983045",
      "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02996110",
      "title": "A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03029780",
      "title": "An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03065179",
      "title": "SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2021-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03075423",
      "title": "Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC",
      "status": "COMPLETED",
      "last_update": "2025-09-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03117309",
      "title": "Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03126331",
      "title": "Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03138512",
      "title": "A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney",
      "status": "COMPLETED",
      "last_update": "2024-12-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03141177",
      "title": "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03149159",
      "title": "Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab",
      "status": "WITHDRAWN",
      "last_update": "2018-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03177239",
      "title": "Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)",
      "status": "UNKNOWN",
      "last_update": "2022-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03203473",
      "title": "Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "status": "COMPLETED",
      "last_update": "2022-09-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03274258",
      "title": "Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03297593",
      "title": "Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03355976",
      "title": "BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03552380",
      "title": "Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2024-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03647163",
      "title": "Ph I/II Trial of Systemic VSV-IFN\u03b2-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03692338",
      "title": "INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-12-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693014",
      "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693612",
      "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03752398",
      "title": "A Study of XmAb\u00ae23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)",
      "status": "COMPLETED",
      "last_update": "2024-07-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03793166",
      "title": "Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816332",
      "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03829111",
      "title": "CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849469",
      "title": "A Study of XmAb\u00ae22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03873402",
      "title": "A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03937219",
      "title": "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03945773",
      "title": "Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors",
      "status": "COMPLETED",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04074967",
      "title": "Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04088500",
      "title": "A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04090710",
      "title": "SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04134182",
      "title": "Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.",
      "status": "UNKNOWN",
      "last_update": "2020-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04140526",
      "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04163289",
      "title": "Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04203901",
      "title": "Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04311710",
      "title": "A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types",
      "status": "TERMINATED",
      "last_update": "2023-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04388852",
      "title": "DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04413123",
      "title": "Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04416568",
      "title": "Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04429321",
      "title": "Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary",
      "status": "TERMINATED",
      "last_update": "2024-04-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04434560",
      "title": "Neoadjuvant Immunotherapy in Brain Metastases",
      "status": "TERMINATED",
      "last_update": "2022-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04495257",
      "title": "A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Na\u00efve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2026-06-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04513522",
      "title": "A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India",
      "status": "COMPLETED",
      "last_update": "2025-07-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04518046",
      "title": "Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-06-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522323",
      "title": "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04606472",
      "title": "A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04714697",
      "title": "Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04940299",
      "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05119010",
      "title": "A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2024-12-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05148546",
      "title": "Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05188118",
      "title": "Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-29",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05215470",
      "title": "CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-07-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256472",
      "title": "A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05293496",
      "title": "A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-10-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05302921",
      "title": "Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05407441",
      "title": "Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05487859",
      "title": "Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05501054",
      "title": "Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05808608",
      "title": "A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05858736",
      "title": "Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05909995",
      "title": "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05928806",
      "title": "Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial",
      "status": "SUSPENDED",
      "last_update": "2026-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06035224",
      "title": "Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06049576",
      "title": "Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06708949",
      "title": "A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07000149",
      "title": "A Study to Investigate the Efficacy and Safety of Volrustomig \u00b1 Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07218692",
      "title": "RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07233668",
      "title": "Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07338981",
      "title": "The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07715565",
      "title": "Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07741617",
      "title": "A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02983045",
       "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2023-03-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab"
    ]
   },
   "CA9": {
    "n": 46,
    "n_observational": 6,
    "n_active": 21,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04969354",
      "title": "Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2021-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05663710",
      "title": "Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na\u00efve Patients With Advanced Clear Cell RCC",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868174",
      "title": "Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447103",
      "title": "An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06519760",
      "title": "68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-11-07",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06613269",
      "title": "68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.",
      "status": "RECRUITING",
      "last_update": "2024-09-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06750419",
      "title": "89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study",
      "status": "RECRUITING",
      "last_update": "2024-12-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07067905",
      "title": "Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-07-16",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07179770",
      "title": "Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07197580",
      "title": "Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07301827",
      "title": "Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07540260",
      "title": "CAIX PET/ CT Guided Radiation Therapy in CcRCC.",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07551349",
      "title": "Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07557225",
      "title": "18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07564232",
      "title": "Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07590310",
      "title": "Clinical Application of CAIX-Targeted PET Imaging in Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07688187",
      "title": "A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003102",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2023-10-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00087022",
      "title": "Monoclonal Antibody Therapy (Rencarex\u00ae) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-11-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199875",
      "title": "Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250",
      "status": "COMPLETED",
      "last_update": "2022-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00199888",
      "title": "Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.",
      "status": "COMPLETED",
      "last_update": "2022-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00203866",
      "title": "Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2013-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00520533",
      "title": "Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00602862",
      "title": "Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250",
      "status": "COMPLETED",
      "last_update": "2013-12-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00606632",
      "title": "Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody",
      "status": "COMPLETED",
      "last_update": "2018-10-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00717587",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00884520",
      "title": "An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037",
      "status": "COMPLETED",
      "last_update": "2010-03-16",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01253668",
      "title": "Brivanib Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01712685",
      "title": "Imaging Studies of Kidney Cancer Using 18F-VM4-037",
      "status": "TERMINATED",
      "last_update": "2017-01-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01762592",
      "title": "REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT",
      "status": "WITHDRAWN",
      "last_update": "2017-12-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01826877",
      "title": "Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02002312",
      "title": "Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02497599",
      "title": "Intraoperative Dual-modality Imaging in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-09-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02883153",
      "title": "Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-06-19",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03556046",
      "title": "89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE",
      "status": "COMPLETED",
      "last_update": "2019-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849118",
      "title": "89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study",
      "status": "COMPLETED",
      "last_update": "2024-05-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04496089",
      "title": "Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC",
      "status": "COMPLETED",
      "last_update": "2021-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239533",
      "title": "Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05698238",
      "title": "Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05728515",
      "title": "A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-02-15",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05861778",
      "title": "Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-12-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05902377",
      "title": "68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06649682",
      "title": "68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC",
      "status": "SUSPENDED",
      "last_update": "2025-12-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06840548",
      "title": "A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer",
      "status": "COMPLETED",
      "last_update": "2026-01-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07077083",
      "title": "CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07101900",
      "title": "68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2025-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04969354",
       "title": "Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma",
       "status": "RECRUITING",
       "last_update": "2021-07-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07551349",
       "title": "Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma",
       "status": "RECRUITING",
       "last_update": "2026-04-24",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CA9",
     "carbonic anhydrase IX",
     "CAIX",
     "girentuximab"
    ]
   },
   "HIF-2alpha": {
    "n": 29,
    "n_observational": 1,
    "n_active": 25,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04989959",
      "title": "[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06234605",
      "title": "A Study of HC-7366 in Combination With Belzutifan (WELIREG\u2122) in Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07023432",
      "title": "Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07049926",
      "title": "Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07167329",
      "title": "Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial",
      "status": "RECRUITING",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07179770",
      "title": "Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07187778",
      "title": "Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227402",
      "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07489495",
      "title": "A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02293980",
      "title": "A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02974738",
      "title": "A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03401788",
      "title": "A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03634540",
      "title": "A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04169711",
      "title": "Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-10-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04195750",
      "title": "A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04489771",
      "title": "A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04586231",
      "title": "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626479",
      "title": "Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626518",
      "title": "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04627064",
      "title": "ABEMA Alone or in COMBO With MK-6482",
      "status": "COMPLETED",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736706",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04846920",
      "title": "A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)",
      "status": "COMPLETED",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05030506",
      "title": "A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05119335",
      "title": "A Study of NKT2152, a HIF2\u03b1 Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2025-11-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239728",
      "title": "A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05468697",
      "title": "A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05899049",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07593040",
      "title": "Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05119335",
       "title": "A Study of NKT2152, a HIF2\u03b1 Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma",
       "status": "TERMINATED",
       "last_update": "2025-11-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "HIF-2",
     "HIF2",
     "belzutifan",
     "Welireg"
    ]
   },
   "CD70": {
    "n": 32,
    "n_observational": 0,
    "n_active": 20,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02830724",
      "title": "Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05518253",
      "title": "A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-05-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06010875",
      "title": "A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2023-11-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06680089",
      "title": "CD70-targeted immunoPET Imaging of Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06769893",
      "title": "A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging",
      "status": "RECRUITING",
      "last_update": "2025-01-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06852638",
      "title": "CD70-targeted immunoPET Imaging of Malignant Cancers",
      "status": "RECRUITING",
      "last_update": "2026-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07072234",
      "title": "Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-04-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07195916",
      "title": "A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07301827",
      "title": "Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-24",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07551349",
      "title": "Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07615348",
      "title": "CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07645690",
      "title": "The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07647744",
      "title": "To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01015911",
      "title": "A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01677390",
      "title": "A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2014-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02216890",
      "title": "Safety Study of SGN-CD70A in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2018-04-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04438083",
      "title": "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)",
      "status": "TERMINATED",
      "last_update": "2025-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04696731",
      "title": "Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05420519",
      "title": "Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05420545",
      "title": "A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05468190",
      "title": "A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T",
      "status": "UNKNOWN",
      "last_update": "2023-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05795595",
      "title": "A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-11-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06148220",
      "title": "A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-02-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06182735",
      "title": "CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-12-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06383507",
      "title": "A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06480565",
      "title": "A Phase 1/2 Trial of ADI-270 in ccRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06586658",
      "title": "Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells",
      "status": "SUSPENDED",
      "last_update": "2026-07-23",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06870279",
      "title": "A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07113977",
      "title": "Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-11",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07181720",
      "title": "CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors",
      "status": "SUSPENDED",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07297160",
      "title": "CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07500805",
      "title": "UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 15,
     "n_observational": 0,
     "n_active": 9,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT02830724",
       "title": "Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers",
       "status": "RECRUITING",
       "last_update": "2026-08-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05518253",
       "title": "A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2025-05-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06010875",
       "title": "A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2023-11-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07072234",
       "title": "Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma",
       "status": "RECRUITING",
       "last_update": "2026-04-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07551349",
       "title": "Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma",
       "status": "RECRUITING",
       "last_update": "2026-04-24",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07645690",
       "title": "The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma",
       "status": "RECRUITING",
       "last_update": "2026-06-22",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05420519",
       "title": "Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer",
       "status": "UNKNOWN",
       "last_update": "2023-08-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05420545",
       "title": "A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2023-08-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05468190",
       "title": "A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T",
       "status": "UNKNOWN",
       "last_update": "2023-08-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06182735",
       "title": "CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma",
       "status": "UNKNOWN",
       "last_update": "2023-12-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06383507",
       "title": "A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2024-04-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06586658",
       "title": "Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells",
       "status": "SUSPENDED",
       "last_update": "2026-07-23",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06870279",
       "title": "A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-04-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07113977",
       "title": "Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2025-08-11",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07181720",
       "title": "CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors",
       "status": "SUSPENDED",
       "last_update": "2026-09-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD70",
     "cusatuzumab"
    ]
   },
   "VEGFR": {
    "n": 415,
    "n_observational": 90,
    "n_active": 122,
    "n_withdrawn": 13,
    "trials": [
     {
      "nct": "NCT03592472",
      "title": "A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)",
      "status": "RECRUITING",
      "last_update": "2025-04-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04510597",
      "title": "Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04777994",
      "title": "Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04823923",
      "title": "Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2025-02-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04977453",
      "title": "GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024214",
      "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05048212",
      "title": "A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05127824",
      "title": "Autologous Dendritic Cell Vaccine in Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05135975",
      "title": "A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263050",
      "title": "Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05319015",
      "title": "Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus",
      "status": "RECRUITING",
      "last_update": "2025-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327686",
      "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05361720",
      "title": "Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05536141",
      "title": "A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05663710",
      "title": "Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na\u00efve Patients With Advanced Clear Cell RCC",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05733715",
      "title": "Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05738694",
      "title": "Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05768464",
      "title": "Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors",
      "status": "RECRUITING",
      "last_update": "2023-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05817903",
      "title": "Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients",
      "status": "RECRUITING",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05931393",
      "title": "Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)",
      "status": "RECRUITING",
      "last_update": "2025-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05969496",
      "title": "Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06026410",
      "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06211114",
      "title": "Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06222593",
      "title": "Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364631",
      "title": "CARE1 Pragmatic Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2025-01-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06690697",
      "title": "Combination of Toripalimab and JS004 Therapy for ccRCC",
      "status": "RECRUITING",
      "last_update": "2024-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06726421",
      "title": "Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835972",
      "title": "A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)",
      "status": "RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06889649",
      "title": "SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC",
      "status": "RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06903312",
      "title": "Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06934057",
      "title": "Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-09-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06962787",
      "title": "A Study of BL-B01D1+TKI\u00b1Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07011719",
      "title": "Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07028125",
      "title": "Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07049926",
      "title": "Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07077161",
      "title": "Cabozantinib Dose Skipping as an Alternative to Dose Reductions",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07087158",
      "title": "A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07097935",
      "title": "Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07123090",
      "title": "A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07172386",
      "title": "Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07175480",
      "title": "PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07187869",
      "title": "Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227402",
      "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227415",
      "title": "Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07293351",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07383441",
      "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07389629",
      "title": "Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07469683",
      "title": "An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07571551",
      "title": "Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07615348",
      "title": "CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744932",
      "title": "SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07805122",
      "title": "Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054886",
      "title": "Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2007-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00076011",
      "title": "Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2012-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089648",
      "title": "SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-01-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00113529",
      "title": "Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00137423",
      "title": "Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2009-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00158782",
      "title": "Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2017-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244764",
      "title": "GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254540",
      "title": "Study of SU011248 in Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2010-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00256880",
      "title": "Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma",
      "status": "COMPLETED",
      "last_update": "2017-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00267748",
      "title": "Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)",
      "status": "COMPLETED",
      "last_update": "2011-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00282048",
      "title": "Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2012-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00326898",
      "title": "Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00334282",
      "title": "Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-02-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00338884",
      "title": "Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2012-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00363194",
      "title": "A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2017-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00372853",
      "title": "Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2012-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00375674",
      "title": "A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00387205",
      "title": "Study To Assess Long Term Safety Of Pazopanib",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00387764",
      "title": "Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2014-01-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397488",
      "title": "Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium",
      "status": "COMPLETED",
      "last_update": "2016-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00399152",
      "title": "Perifosine + Sunitinib Malate for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2014-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00401583",
      "title": "A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes",
      "status": "COMPLETED",
      "last_update": "2017-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00410124",
      "title": "RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00417677",
      "title": "A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2007-12-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00421512",
      "title": "A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2008-11-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00422344",
      "title": "A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-02-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00444314",
      "title": "Phase 2 Study of Panzem\u00ae NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00459875",
      "title": "Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2015-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00462982",
      "title": "Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00465179",
      "title": "Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471536",
      "title": "Pazopanib in Treating Patients With Metastatic Urothelial Cancer",
      "status": "COMPLETED",
      "last_update": "2014-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00474786",
      "title": "Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-11-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478725",
      "title": "Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034",
      "status": "COMPLETED",
      "last_update": "2017-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00480935",
      "title": "A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00486538",
      "title": "Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00491738",
      "title": "A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)",
      "status": "TERMINATED",
      "last_update": "2009-04-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00498966",
      "title": "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney",
      "status": "COMPLETED",
      "last_update": "2018-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00499135",
      "title": "Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00502307",
      "title": "A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00516672",
      "title": "Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00520533",
      "title": "Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00522249",
      "title": "Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC",
      "status": "TERMINATED",
      "last_update": "2016-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00531544",
      "title": "A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248",
      "status": "COMPLETED",
      "last_update": "2016-01-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00541008",
      "title": "Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556049",
      "title": "Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556205",
      "title": "Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2016-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00566995",
      "title": "Phase II Study of Vandetanib in Individuals With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00569946",
      "title": "Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)",
      "status": "COMPLETED",
      "last_update": "2019-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00570882",
      "title": "Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2014-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00619268",
      "title": "Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2013-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00655655",
      "title": "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00663559",
      "title": "Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy",
      "status": "COMPLETED",
      "last_update": "2014-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678119",
      "title": "Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment",
      "status": "COMPLETED",
      "last_update": "2013-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678288",
      "title": "A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.",
      "status": "TERMINATED",
      "last_update": "2014-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678392",
      "title": "Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2019-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00694096",
      "title": "Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response",
      "status": "COMPLETED",
      "last_update": "2015-12-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00706706",
      "title": "Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00709995",
      "title": "A Study for Participants With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00715442",
      "title": "Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00717587",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720941",
      "title": "Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00731211",
      "title": "Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00732914",
      "title": "Sequential Study to Treat Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-04-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00747305",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery",
      "status": "TERMINATED",
      "last_update": "2015-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00749320",
      "title": "Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2020-02-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00788060",
      "title": "A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00792025",
      "title": "Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00814021",
      "title": "Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain",
      "status": "COMPLETED",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00835978",
      "title": "Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2017-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00849186",
      "title": "Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2015-02-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00853125",
      "title": "Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2021-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00853372",
      "title": "AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2020-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00861029",
      "title": "VEG111485: A QTc Study of Pazopanib",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00866320",
      "title": "Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2014-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00869011",
      "title": "Exercise for Patients With Renal Cell Cancer Receiving Sunitinib",
      "status": "UNKNOWN",
      "last_update": "2009-12-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00890110",
      "title": "Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib",
      "status": "UNKNOWN",
      "last_update": "2009-04-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00891475",
      "title": "Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2014-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00903175",
      "title": "Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00920816",
      "title": "Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2022-05-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00930033",
      "title": "Clinical Trial to Assess the Importance of Nephrectomy",
      "status": "COMPLETED",
      "last_update": "2025-09-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00930345",
      "title": "Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-04-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00943839",
      "title": "Sunitinib Malate in Treating Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2016-11-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00953446",
      "title": "Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2020-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00975806",
      "title": "Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00979966",
      "title": "Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib",
      "status": "COMPLETED",
      "last_update": "2012-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982657",
      "title": "A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992121",
      "title": "An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01012362",
      "title": "Study of Pazopanib and Ixabepilone in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01024205",
      "title": "Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2013-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01024920",
      "title": "Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.",
      "status": "COMPLETED",
      "last_update": "2021-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01031875",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment",
      "status": "COMPLETED",
      "last_update": "2013-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01034878",
      "title": "Sunitinib in Metastatic Renal Cancer",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01061411",
      "title": "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01064310",
      "title": "Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01069770",
      "title": "Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)",
      "status": "UNKNOWN",
      "last_update": "2011-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01070186",
      "title": "Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2012-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01089088",
      "title": "Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)",
      "status": "COMPLETED",
      "last_update": "2018-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01099423",
      "title": "Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01100619",
      "title": "A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108445",
      "title": "Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2018-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01118039",
      "title": "Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01130623",
      "title": "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01136733",
      "title": "A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment",
      "status": "COMPLETED",
      "last_update": "2019-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01141569",
      "title": "A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy",
      "status": "COMPLETED",
      "last_update": "2017-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01147822",
      "title": "Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01157091",
      "title": "Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01158222",
      "title": "Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01158521",
      "title": "Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164228",
      "title": "Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01184326",
      "title": "Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer",
      "status": "COMPLETED",
      "last_update": "2019-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01202032",
      "title": "Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2016-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216371",
      "title": "Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)",
      "status": "TERMINATED",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01217931",
      "title": "Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01218867",
      "title": "CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2019-12-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01219751",
      "title": "Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2011-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01221506",
      "title": "Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2020-03-26",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01235962",
      "title": "A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2020-11-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01258348",
      "title": "A Phase 1b Trial in Patients With Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01263769",
      "title": "Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01334073",
      "title": "Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01361113",
      "title": "Neoadjuvant Pazopanib in Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2018-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392183",
      "title": "Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2021-09-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392352",
      "title": "HYPAZ: Hypertension Induced by Pazopanib",
      "status": "TERMINATED",
      "last_update": "2020-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01402089",
      "title": "Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2016-02-02",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01408004",
      "title": "Rotating Pazopanib and Everolimus to Avoid Resistance",
      "status": "COMPLETED",
      "last_update": "2014-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01435122",
      "title": "A Study of Axitinib in Advanced Carcinoid Tumors",
      "status": "COMPLETED",
      "last_update": "2018-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441414",
      "title": "PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472081",
      "title": "Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",
      "status": "COMPLETED",
      "last_update": "2021-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01481870",
      "title": "Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2013-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01482949",
      "title": "A Rollover Protocol for Subjects Previously Treated With AGS-003",
      "status": "TERMINATED",
      "last_update": "2018-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01502228",
      "title": "PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-03-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01513187",
      "title": "Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01514448",
      "title": "Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib",
      "status": "COMPLETED",
      "last_update": "2017-07-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01517243",
      "title": "Phase II Study of Alternating Sunitinib and Temsirolimus",
      "status": "COMPLETED",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01521715",
      "title": "First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-08-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01538238",
      "title": "pazopanib_NCRCC,Ph2 STUDY",
      "status": "COMPLETED",
      "last_update": "2017-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01545817",
      "title": "Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01566747",
      "title": "Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5",
      "status": "COMPLETED",
      "last_update": "2021-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01575548",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01577784",
      "title": "Pazopanib in Second-line Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2014-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01582009",
      "title": "Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate",
      "status": "TERMINATED",
      "last_update": "2022-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01582204",
      "title": "Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01599754",
      "title": "Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients",
      "status": "TERMINATED",
      "last_update": "2019-09-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01599832",
      "title": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2017-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01613846",
      "title": "Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)",
      "status": "COMPLETED",
      "last_update": "2017-04-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01616186",
      "title": "Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2013-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01622660",
      "title": "Gemcitabine and Pazopanib in Chemotherapy Na\u00efve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy",
      "status": "TERMINATED",
      "last_update": "2017-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01649180",
      "title": "NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01664182",
      "title": "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01673386",
      "title": "A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC",
      "status": "TERMINATED",
      "last_update": "2020-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01684397",
      "title": "Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01688999",
      "title": "Cabozantinib for Advanced Urothelial Cancer",
      "status": "COMPLETED",
      "last_update": "2022-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01693822",
      "title": "A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy",
      "status": "COMPLETED",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01727336",
      "title": "Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01731158",
      "title": "Sequential Therapy in Metastatic Renal Cell Carinoma",
      "status": "COMPLETED",
      "last_update": "2019-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01740154",
      "title": "Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2018-12-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01743300",
      "title": "The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2012-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01767636",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01769885",
      "title": "Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer",
      "status": "WITHDRAWN",
      "last_update": "2022-08-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01784978",
      "title": "Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer",
      "status": "TERMINATED",
      "last_update": "2017-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01798446",
      "title": "A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01806064",
      "title": "Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01835158",
      "title": "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01865747",
      "title": "A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-04-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01961583",
      "title": "[18F]Fluciclatide PET Imaging of Pazopanib Response",
      "status": "TERMINATED",
      "last_update": "2016-03-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01984242",
      "title": "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin\u00ae) Compared to Sunitinib (Sutent\u00ae) in Participants With Untreated Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01999972",
      "title": "A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02014636",
      "title": "Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)",
      "status": "COMPLETED",
      "last_update": "2020-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02019576",
      "title": "Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2021-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02060370",
      "title": "Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2020-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02071641",
      "title": "Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2017-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02071862",
      "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02072031",
      "title": "Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma\uff08RCC\uff09",
      "status": "UNKNOWN",
      "last_update": "2016-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02089802",
      "title": "Optimizing Pazopanib Exposure in RCC Patients",
      "status": "TERMINATED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02122003",
      "title": "Second Line Sorafenib After Pazopanib in Patients With RCC",
      "status": "TERMINATED",
      "last_update": "2017-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02133742",
      "title": "A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2021-07-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02187302",
      "title": "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)",
      "status": "COMPLETED",
      "last_update": "2020-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02208128",
      "title": "Molecular Determinants for Therapy Response on Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2014-08-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02219711",
      "title": "Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2023-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02231749",
      "title": "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02293980",
      "title": "A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02307474",
      "title": "A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer",
      "status": "WITHDRAWN",
      "last_update": "2016-03-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02324803",
      "title": "Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients",
      "status": "UNKNOWN",
      "last_update": "2014-12-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02386111",
      "title": "A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2018-07-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02406521",
      "title": "Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets",
      "status": "COMPLETED",
      "last_update": "2020-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420821",
      "title": "A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2023-01-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02432846",
      "title": "Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2022-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02446795",
      "title": "Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial",
      "status": "UNKNOWN",
      "last_update": "2017-01-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02454478",
      "title": "Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2019-03-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02479490",
      "title": "PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI",
      "status": "TERMINATED",
      "last_update": "2018-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02489695",
      "title": "Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02493751",
      "title": "A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)",
      "status": "COMPLETED",
      "last_update": "2022-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02496208",
      "title": "Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535351",
      "title": "Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery",
      "status": "TERMINATED",
      "last_update": "2018-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535533",
      "title": "SLM + Axitinib for Clear Cell RCC",
      "status": "COMPLETED",
      "last_update": "2026-05-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02555748",
      "title": "Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02560012",
      "title": "Personalized Targeted Inhibitors Treatment in Renal Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02570789",
      "title": "Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy",
      "status": "TERMINATED",
      "last_update": "2021-03-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02579811",
      "title": "Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2023-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02597322",
      "title": "Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)",
      "status": "COMPLETED",
      "last_update": "2025-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626754",
      "title": "A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population",
      "status": "TERMINATED",
      "last_update": "2018-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02639182",
      "title": "A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02667886",
      "title": "Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02684006",
      "title": "A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02688491",
      "title": "A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment",
      "status": "UNKNOWN",
      "last_update": "2016-02-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02689167",
      "title": "Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02700568",
      "title": "Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors",
      "status": "COMPLETED",
      "last_update": "2019-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02729194",
      "title": "Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-06-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02761057",
      "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02795819",
      "title": "Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2019-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02811861",
      "title": "Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853331",
      "title": "Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)",
      "status": "COMPLETED",
      "last_update": "2026-02-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02915783",
      "title": "A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease",
      "status": "COMPLETED",
      "last_update": "2023-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02956798",
      "title": "SAbR For Oligometastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959554",
      "title": "Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control",
      "status": "TERMINATED",
      "last_update": "2021-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02960906",
      "title": "A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Na\u00efve Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03006887",
      "title": "Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013946",
      "title": "Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy",
      "status": "TERMINATED",
      "last_update": "2025-02-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03035630",
      "title": "Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2022-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03062410",
      "title": "Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-07-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03066427",
      "title": "Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.",
      "status": "COMPLETED",
      "last_update": "2020-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03086174",
      "title": "Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03091192",
      "title": "Savolitinib vs. Sunitinib in MET-driven PRCC.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03092856",
      "title": "Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03109015",
      "title": "Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing",
      "status": "COMPLETED",
      "last_update": "2024-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03141177",
      "title": "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03149822",
      "title": "Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03172754",
      "title": "Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03173560",
      "title": "Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03200587",
      "title": "Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2024-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03200717",
      "title": "Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment",
      "status": "COMPLETED",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03260894",
      "title": "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)",
      "status": "COMPLETED",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03323710",
      "title": "Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2019-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03324373",
      "title": "Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03334409",
      "title": "Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2022-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03339219",
      "title": "A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-09-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03341845",
      "title": "Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC",
      "status": "UNKNOWN",
      "last_update": "2018-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03354884",
      "title": "caBozantinib in cOllectiNg ductS Renal Cell cArcInoma",
      "status": "COMPLETED",
      "last_update": "2021-05-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03379012",
      "title": "Testosterone in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2019-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03428217",
      "title": "CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03438708",
      "title": "Prior Axitinib as a Determinant of Outcome of Renal Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03456401",
      "title": "Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)",
      "status": "TERMINATED",
      "last_update": "2018-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03463681",
      "title": "A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03494816",
      "title": "Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion",
      "status": "COMPLETED",
      "last_update": "2021-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03541902",
      "title": "Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571438",
      "title": "Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-01-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03592199",
      "title": "Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib",
      "status": "UNKNOWN",
      "last_update": "2019-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03595124",
      "title": "A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03606174",
      "title": "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-08-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03634540",
      "title": "A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03635892",
      "title": "A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03680521",
      "title": "Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-10-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03685448",
      "title": "ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)",
      "status": "COMPLETED",
      "last_update": "2025-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03729245",
      "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)",
      "status": "TERMINATED",
      "last_update": "2023-04-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03736330",
      "title": "A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-11-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03793166",
      "title": "Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03798626",
      "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",
      "status": "COMPLETED",
      "last_update": "2026-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03867045",
      "title": "Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer",
      "status": "TERMINATED",
      "last_update": "2021-06-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03875313",
      "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03905889",
      "title": "A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03937219",
      "title": "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03945773",
      "title": "Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors",
      "status": "COMPLETED",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03967522",
      "title": "Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2025-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04022343",
      "title": "Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04071223",
      "title": "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04118855",
      "title": "Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04134390",
      "title": "Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study",
      "status": "COMPLETED",
      "last_update": "2024-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04203901",
      "title": "Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04267120",
      "title": "Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)",
      "status": "TERMINATED",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04300140",
      "title": "Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-10-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04322955",
      "title": "CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04337970",
      "title": "Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04338269",
      "title": "A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment",
      "status": "TERMINATED",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370509",
      "title": "Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery",
      "status": "TERMINATED",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04385654",
      "title": "Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04387500",
      "title": "Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04393350",
      "title": "Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04394975",
      "title": "Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2025-11-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04413123",
      "title": "Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04462445",
      "title": "Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb",
      "status": "COMPLETED",
      "last_update": "2020-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04508725",
      "title": "Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2025-07-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04514484",
      "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522323",
      "title": "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04523272",
      "title": "A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04540705",
      "title": "A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread",
      "status": "COMPLETED",
      "last_update": "2024-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04586231",
      "title": "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626479",
      "title": "Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626518",
      "title": "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644432",
      "title": "Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04698213",
      "title": "Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04704219",
      "title": "Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04714697",
      "title": "Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736706",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04764487",
      "title": "A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line",
      "status": "UNKNOWN",
      "last_update": "2022-05-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955743",
      "title": "Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04958473",
      "title": "A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04995016",
      "title": "Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05012371",
      "title": "Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05030506",
      "title": "A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05043090",
      "title": "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092958",
      "title": "Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05096390",
      "title": "Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC",
      "status": "UNKNOWN",
      "last_update": "2024-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05122546",
      "title": "CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05172440",
      "title": "A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC",
      "status": "UNKNOWN",
      "last_update": "2021-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176288",
      "title": "Avelumab, Palbociclib and Axitinib in Advanced RCC",
      "status": "WITHDRAWN",
      "last_update": "2023-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05188118",
      "title": "Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-29",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05219318",
      "title": "Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05241561",
      "title": "Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256472",
      "title": "A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05262413",
      "title": "A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)",
      "status": "UNKNOWN",
      "last_update": "2022-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263245",
      "title": "The Pharmacological Effects of Using Cabozantinib With a Light Breakfast",
      "status": "COMPLETED",
      "last_update": "2025-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263609",
      "title": "Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib",
      "status": "WITHDRAWN",
      "last_update": "2022-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05363631",
      "title": "Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05411081",
      "title": "Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05485883",
      "title": "Tislelizumab Plus Lenvatinib in Stage III-IV RCC",
      "status": "UNKNOWN",
      "last_update": "2022-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05485896",
      "title": "Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05487859",
      "title": "Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05522231",
      "title": "Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-03",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05678673",
      "title": "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800106",
      "title": "A Bioequivalence Study of Sunitinib Malate Capsules.",
      "status": "COMPLETED",
      "last_update": "2023-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05805501",
      "title": "A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05808608",
      "title": "A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05816642",
      "title": "Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05877820",
      "title": "A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC",
      "status": "COMPLETED",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05899049",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949424",
      "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06032728",
      "title": "Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06035224",
      "title": "Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06114940",
      "title": "Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)",
      "status": "TERMINATED",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06129955",
      "title": "Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06132945",
      "title": "A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06138496",
      "title": "Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06279403",
      "title": "Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06377722",
      "title": "Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer",
      "status": "TERMINATED",
      "last_update": "2024-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390826",
      "title": "Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06574412",
      "title": "Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06583369",
      "title": "The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs",
      "status": "UNKNOWN",
      "last_update": "2024-09-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06716853",
      "title": "A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-02-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860386",
      "title": "Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC",
      "status": "SUSPENDED",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07011849",
      "title": "Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases",
      "status": "WITHDRAWN",
      "last_update": "2025-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07159191",
      "title": "Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07165418",
      "title": "A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07252661",
      "title": "Study of ACC-1898 in Adult Participants With Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07256223",
      "title": "A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07277972",
      "title": "Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07460206",
      "title": "Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07500831",
      "title": "Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07593040",
      "title": "Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07620574",
      "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07630363",
      "title": "PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07715565",
      "title": "Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07741617",
      "title": "A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07776717",
      "title": "TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 4,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT00853125",
       "title": "Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer",
       "status": "TERMINATED",
       "last_update": "2021-04-27",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01218867",
       "title": "CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer",
       "status": "TERMINATED",
       "last_update": "2019-12-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03729245",
       "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)",
       "status": "TERMINATED",
       "last_update": "2023-04-11",
       "phase": "PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04540705",
       "title": "A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread",
       "status": "COMPLETED",
       "last_update": "2024-02-28",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "VEGFR",
     "sunitinib",
     "pazopanib",
     "axitinib",
     "cabozantinib",
     "lenvatinib"
    ]
   }
  },
  "by_drug": {
   "ADEBRELIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07239596",
      "title": "Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ATEZOLIZUMAB": {
    "n": 47,
    "n_observational": 3,
    "n_active": 18,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT04981509",
      "title": "Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05765084",
      "title": "Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05944237",
      "title": "HTL0039732 in Participants With Advanced Solid Tumours",
      "status": "RECRUITING",
      "last_update": "2025-06-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06161532",
      "title": "Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06332755",
      "title": "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC",
      "status": "RECRUITING",
      "last_update": "2025-11-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01984242",
      "title": "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin\u00ae) Compared to Sunitinib (Sutent\u00ae) in Participants With Untreated Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420821",
      "title": "A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2023-01-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02543645",
      "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2018-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02655822",
      "title": "Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2021-08-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02724878",
      "title": "Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992912",
      "title": "Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours",
      "status": "COMPLETED",
      "last_update": "2026-09-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03024437",
      "title": "Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2025-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03024996",
      "title": "A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy",
      "status": "TERMINATED",
      "last_update": "2023-08-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03050060",
      "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2022-06-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03063762",
      "title": "Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2023-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03115801",
      "title": "A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers",
      "status": "TERMINATED",
      "last_update": "2021-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03237780",
      "title": "Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03289962",
      "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
      "status": "COMPLETED",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03511391",
      "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03513952",
      "title": "Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-07-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693014",
      "title": "A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03693573",
      "title": "A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2018-11-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03829501",
      "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-04-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03841110",
      "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03845166",
      "title": "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03961698",
      "title": "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04006522",
      "title": "89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04157985",
      "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04338269",
      "title": "A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment",
      "status": "TERMINATED",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04504669",
      "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours",
      "status": "COMPLETED",
      "last_update": "2024-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04637594",
      "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05259319",
      "title": "Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)",
      "status": "UNKNOWN",
      "last_update": "2023-10-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05286801",
      "title": "Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05411081",
      "title": "Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05564416",
      "title": "Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial",
      "status": "WITHDRAWN",
      "last_update": "2025-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05581004",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06090318",
      "title": "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss",
      "status": "WITHDRAWN",
      "last_update": "2023-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07620574",
      "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AVELUMAB": {
    "n": 31,
    "n_observational": 8,
    "n_active": 10,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04510597",
      "title": "Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327686",
      "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01772004",
      "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)",
      "status": "COMPLETED",
      "last_update": "2021-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02493751",
      "title": "A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)",
      "status": "COMPLETED",
      "last_update": "2022-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02684006",
      "title": "A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013946",
      "title": "Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy",
      "status": "TERMINATED",
      "last_update": "2025-02-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03035630",
      "title": "Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2022-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03200587",
      "title": "Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2024-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03341845",
      "title": "Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC",
      "status": "UNKNOWN",
      "last_update": "2018-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475953",
      "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-03-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03483883",
      "title": "Avelumab/Gemcitabine in Sarcomatoid RCC",
      "status": "TERMINATED",
      "last_update": "2022-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03617913",
      "title": "Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer",
      "status": "COMPLETED",
      "last_update": "2023-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03815643",
      "title": "Avelumab Program Rollover Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03845166",
      "title": "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-11-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04004442",
      "title": "Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04068831",
      "title": "Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-12-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04150562",
      "title": "Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04260802",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers",
      "status": "TERMINATED",
      "last_update": "2026-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04551885",
      "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04637594",
      "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04698213",
      "title": "Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04714697",
      "title": "Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04848519",
      "title": "Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04871529",
      "title": "Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)",
      "status": "TERMINATED",
      "last_update": "2024-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05069935",
      "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092958",
      "title": "Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176288",
      "title": "Avelumab, Palbociclib and Axitinib in Advanced RCC",
      "status": "WITHDRAWN",
      "last_update": "2023-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AXITINIB": {
    "n": 94,
    "n_observational": 25,
    "n_active": 35,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT04510597",
      "title": "Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial",
      "status": "RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327686",
      "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05738694",
      "title": "Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05768464",
      "title": "Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors",
      "status": "RECRUITING",
      "last_update": "2023-03-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05817903",
      "title": "Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients",
      "status": "RECRUITING",
      "last_update": "2023-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05969496",
      "title": "Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06211114",
      "title": "Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364631",
      "title": "CARE1 Pragmatic Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2025-01-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06690697",
      "title": "Combination of Toripalimab and JS004 Therapy for ccRCC",
      "status": "RECRUITING",
      "last_update": "2024-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06726421",
      "title": "Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06889649",
      "title": "SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC",
      "status": "RECRUITING",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06903312",
      "title": "Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06962787",
      "title": "A Study of BL-B01D1+TKI\u00b1Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07123090",
      "title": "A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07172386",
      "title": "Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC",
      "status": "RECRUITING",
      "last_update": "2025-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227415",
      "title": "Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07383441",
      "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07469683",
      "title": "An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07744932",
      "title": "SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00076011",
      "title": "Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2012-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00282048",
      "title": "Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2012-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00569946",
      "title": "Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)",
      "status": "COMPLETED",
      "last_update": "2019-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678392",
      "title": "Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2019-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00835978",
      "title": "Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2017-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00920816",
      "title": "Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2022-05-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01263769",
      "title": "Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01334073",
      "title": "Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-05-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01435122",
      "title": "A Study of Axitinib in Advanced Carcinoid Tumors",
      "status": "COMPLETED",
      "last_update": "2018-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441414",
      "title": "PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-01-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01599754",
      "title": "Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients",
      "status": "TERMINATED",
      "last_update": "2019-09-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01649180",
      "title": "NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01693822",
      "title": "A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy",
      "status": "COMPLETED",
      "last_update": "2024-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01727336",
      "title": "Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01798446",
      "title": "A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus",
      "status": "COMPLETED",
      "last_update": "2020-12-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01806064",
      "title": "Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01999972",
      "title": "A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02133742",
      "title": "A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2021-07-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02187302",
      "title": "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)",
      "status": "COMPLETED",
      "last_update": "2020-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02208128",
      "title": "Molecular Determinants for Therapy Response on Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2014-08-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02489695",
      "title": "Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02493751",
      "title": "A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)",
      "status": "COMPLETED",
      "last_update": "2022-02-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535533",
      "title": "SLM + Axitinib for Clear Cell RCC",
      "status": "COMPLETED",
      "last_update": "2026-05-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02560012",
      "title": "Personalized Targeted Inhibitors Treatment in Renal Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02579811",
      "title": "Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2023-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02597322",
      "title": "Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)",
      "status": "COMPLETED",
      "last_update": "2025-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02639182",
      "title": "A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02667886",
      "title": "Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-10-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02684006",
      "title": "A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02700568",
      "title": "Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors",
      "status": "COMPLETED",
      "last_update": "2019-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853331",
      "title": "Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)",
      "status": "COMPLETED",
      "last_update": "2026-02-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013946",
      "title": "Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy",
      "status": "TERMINATED",
      "last_update": "2025-02-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03086174",
      "title": "Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma",
      "status": "UNKNOWN",
      "last_update": "2020-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03092856",
      "title": "Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03172754",
      "title": "Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03341845",
      "title": "Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC",
      "status": "UNKNOWN",
      "last_update": "2018-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03438708",
      "title": "Prior Axitinib as a Determinant of Outcome of Renal Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03494816",
      "title": "Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion",
      "status": "COMPLETED",
      "last_update": "2021-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03592199",
      "title": "Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib",
      "status": "UNKNOWN",
      "last_update": "2019-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03595124",
      "title": "A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03736330",
      "title": "A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-11-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04118855",
      "title": "Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04337970",
      "title": "Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04370509",
      "title": "Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery",
      "status": "TERMINATED",
      "last_update": "2025-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04385654",
      "title": "Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04387500",
      "title": "Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2024-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04394975",
      "title": "Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2025-11-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522323",
      "title": "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04540705",
      "title": "A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread",
      "status": "COMPLETED",
      "last_update": "2024-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04698213",
      "title": "Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04714697",
      "title": "Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04764487",
      "title": "A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line",
      "status": "UNKNOWN",
      "last_update": "2022-05-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04958473",
      "title": "A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-07-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04995016",
      "title": "Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05096390",
      "title": "Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC",
      "status": "UNKNOWN",
      "last_update": "2024-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05172440",
      "title": "A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC",
      "status": "UNKNOWN",
      "last_update": "2021-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176288",
      "title": "Avelumab, Palbociclib and Axitinib in Advanced RCC",
      "status": "WITHDRAWN",
      "last_update": "2023-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05256472",
      "title": "A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263609",
      "title": "Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib",
      "status": "WITHDRAWN",
      "last_update": "2022-08-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05363631",
      "title": "Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05522231",
      "title": "Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-03",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05805501",
      "title": "A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05808608",
      "title": "A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05816642",
      "title": "Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06279403",
      "title": "Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06583369",
      "title": "The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs",
      "status": "UNKNOWN",
      "last_update": "2024-09-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06860386",
      "title": "Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC",
      "status": "SUSPENDED",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07159191",
      "title": "Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07277972",
      "title": "Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07500831",
      "title": "Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07630363",
      "title": "PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07776717",
      "title": "TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BELZUTIFAN": {
    "n": 27,
    "n_observational": 1,
    "n_active": 25,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04989959",
      "title": "[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06234605",
      "title": "A Study of HC-7366 in Combination With Belzutifan (WELIREG\u2122) in Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07023432",
      "title": "Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07049926",
      "title": "Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07167329",
      "title": "Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial",
      "status": "RECRUITING",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07179770",
      "title": "Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07187778",
      "title": "Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227402",
      "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07489495",
      "title": "A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02293980",
      "title": "A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02974738",
      "title": "A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03401788",
      "title": "A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03634540",
      "title": "A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04195750",
      "title": "A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04489771",
      "title": "A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04586231",
      "title": "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626479",
      "title": "Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626518",
      "title": "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04627064",
      "title": "ABEMA Alone or in COMBO With MK-6482",
      "status": "COMPLETED",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736706",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04846920",
      "title": "A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)",
      "status": "COMPLETED",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05030506",
      "title": "A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239728",
      "title": "A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05468697",
      "title": "A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05899049",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07593040",
      "title": "Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BINTRAFUSP ALFA": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04235777",
      "title": "Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04648826",
      "title": "Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2021-12-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BRIVANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01253668",
      "title": "Brivanib Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BRIVANIB ALANINATE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01253668",
      "title": "Brivanib Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-04-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CABOZANTINIB": {
    "n": 79,
    "n_observational": 21,
    "n_active": 49,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04823923",
      "title": "Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2025-02-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05048212",
      "title": "A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases",
      "status": "RECRUITING",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05127824",
      "title": "Autologous Dendritic Cell Vaccine in Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05135975",
      "title": "A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263050",
      "title": "Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327686",
      "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05361720",
      "title": "Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study",
      "status": "RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05536141",
      "title": "A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05663710",
      "title": "Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na\u00efve Patients With Advanced Clear Cell RCC",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05931393",
      "title": "Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)",
      "status": "RECRUITING",
      "last_update": "2025-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06026410",
      "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364631",
      "title": "CARE1 Pragmatic Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2025-01-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06726421",
      "title": "Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835972",
      "title": "A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)",
      "status": "RECRUITING",
      "last_update": "2026-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06903312",
      "title": "Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06934057",
      "title": "Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-09-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07011719",
      "title": "Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07028125",
      "title": "Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07077161",
      "title": "Cabozantinib Dose Skipping as an Alternative to Dose Reductions",
      "status": "RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07187869",
      "title": "Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07227402",
      "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07293351",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07383441",
      "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07805122",
      "title": "Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01100619",
      "title": "A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01688999",
      "title": "Cabozantinib for Advanced Urothelial Cancer",
      "status": "COMPLETED",
      "last_update": "2022-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01835158",
      "title": "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01865747",
      "title": "A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-04-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02071862",
      "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02293980",
      "title": "A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02496208",
      "title": "Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02761057",
      "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03141177",
      "title": "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03149822",
      "title": "Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-08-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03200587",
      "title": "Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2024-07-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03339219",
      "title": "A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-09-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03354884",
      "title": "caBozantinib in cOllectiNg ductS Renal Cell cArcInoma",
      "status": "COMPLETED",
      "last_update": "2021-05-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03428217",
      "title": "CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-03-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03463681",
      "title": "A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03541902",
      "title": "Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03634540",
      "title": "A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03635892",
      "title": "A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03685448",
      "title": "ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)",
      "status": "COMPLETED",
      "last_update": "2025-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03729245",
      "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)",
      "status": "TERMINATED",
      "last_update": "2023-04-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03793166",
      "title": "Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03798626",
      "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",
      "status": "COMPLETED",
      "last_update": "2026-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03867045",
      "title": "Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer",
      "status": "TERMINATED",
      "last_update": "2021-06-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03937219",
      "title": "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03945773",
      "title": "Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors",
      "status": "COMPLETED",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03967522",
      "title": "Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases",
      "status": "COMPLETED",
      "last_update": "2025-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04022343",
      "title": "Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04071223",
      "title": "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04134390",
      "title": "Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study",
      "status": "COMPLETED",
      "last_update": "2024-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04300140",
      "title": "Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-10-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04322955",
      "title": "CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04338269",
      "title": "A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment",
      "status": "TERMINATED",
      "last_update": "2026-03-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04413123",
      "title": "Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04514484",
      "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04540705",
      "title": "A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread",
      "status": "COMPLETED",
      "last_update": "2024-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04586231",
      "title": "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644432",
      "title": "Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04714697",
      "title": "Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05012371",
      "title": "Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092958",
      "title": "Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05122546",
      "title": "CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05188118",
      "title": "Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-29",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05241561",
      "title": "Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05263245",
      "title": "The Pharmacological Effects of Using Cabozantinib With a Light Breakfast",
      "status": "COMPLETED",
      "last_update": "2025-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05411081",
      "title": "Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05487859",
      "title": "Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06132945",
      "title": "A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06377722",
      "title": "Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer",
      "status": "TERMINATED",
      "last_update": "2024-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06716853",
      "title": "A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-02-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07620574",
      "title": "Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-08-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CABOZANTINIB S-MALATE": {
    "n": 11,
    "n_observational": 0,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01835158",
      "title": "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02496208",
      "title": "Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02761057",
      "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04071223",
      "title": "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04514484",
      "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05092958",
      "title": "Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05122546",
      "title": "CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05411081",
      "title": "Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CAPMATINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01324479",
      "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02019693",
      "title": "A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2023-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02386826",
      "title": "INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme",
      "status": "COMPLETED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CATEQUENTINIB": {
    "n": 9,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06211790",
      "title": "Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2024-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02072031",
      "title": "Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma\uff08RCC\uff09",
      "status": "UNKNOWN",
      "last_update": "2016-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02072044",
      "title": "Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy",
      "status": "UNKNOWN",
      "last_update": "2017-12-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04523272",
      "title": "A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05124431",
      "title": "Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05220267",
      "title": "Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07470840",
      "title": "SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07602101",
      "title": "Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07627464",
      "title": "Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CEDIRANIB": {
    "n": 6,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00227760",
      "title": "Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2016-02-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00303862",
      "title": "AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2014-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00423332",
      "title": "Cediranib (AZD2171, RECENTIN\u2122) in Metastatic or Recurrent Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-02-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00937482",
      "title": "Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer",
      "status": "TERMINATED",
      "last_update": "2013-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01131234",
      "title": "Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03741426",
      "title": "WIRE - Novel Treatments in Renal Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CM-082": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02577458",
      "title": "Study of the Combination of CM082 With Everolimus in Patients With mRCC",
      "status": "UNKNOWN",
      "last_update": "2018-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03095040",
      "title": "CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06577961",
      "title": "Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07047001",
      "title": "Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COSIBELIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07426484",
      "title": "Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy",
      "status": "RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03212404",
      "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CRIZOTINIB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01524926",
      "title": "CREATE: Cross-tumoral Phase 2 With Crizotinib",
      "status": "COMPLETED",
      "last_update": "2023-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01999972",
      "title": "A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568267",
      "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02761057",
      "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644432",
      "title": "Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2020-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DACTOLISIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01453595",
      "title": "BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)",
      "status": "TERMINATED",
      "last_update": "2016-02-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01482156",
      "title": "Dose Finding Study of RAD001 (Everolimus, Afinitor\u00ae) in Combination With BEZ235 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DOVITINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01223027",
      "title": "Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-12-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01714765",
      "title": "Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer",
      "status": "COMPLETED",
      "last_update": "2013-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01791387",
      "title": "1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC",
      "status": "UNKNOWN",
      "last_update": "2015-02-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DS-3078A": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01588678",
      "title": "A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",
      "status": "COMPLETED",
      "last_update": "2019-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DURVALUMAB": {
    "n": 24,
    "n_observational": 2,
    "n_active": 10,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03288532",
      "title": "Renal Adjuvant MultiPle Arm Randomised Trial",
      "status": "RECRUITING",
      "last_update": "2020-09-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04628767",
      "title": "Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01975831",
      "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab",
      "status": "COMPLETED",
      "last_update": "2022-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02118337",
      "title": "A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2021-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02669914",
      "title": "MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors",
      "status": "TERMINATED",
      "last_update": "2018-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02762006",
      "title": "Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02812420",
      "title": "Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02819596",
      "title": "MEDI4736 Combinations in Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03308396",
      "title": "Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2022-02-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "status": "UNKNOWN",
      "last_update": "2020-06-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03598816",
      "title": "PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2020-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03682068",
      "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03682289",
      "title": "Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03741426",
      "title": "WIRE - Novel Treatments in Renal Cell Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03983954",
      "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04262375",
      "title": "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION",
      "status": "WITHDRAWN",
      "last_update": "2020-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04504669",
      "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours",
      "status": "COMPLETED",
      "last_update": "2024-11-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04631731",
      "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity",
      "status": "UNKNOWN",
      "last_update": "2023-06-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04637594",
      "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04902040",
      "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",
      "status": "TERMINATED",
      "last_update": "2026-04-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05043090",
      "title": "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05429866",
      "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2023-03-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EMIBETUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02082210",
      "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ENVAFOLIMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05024214",
      "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07159191",
      "title": "Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07256223",
      "title": "A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FAMITINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01829841",
      "title": "A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03827837",
      "title": "Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors",
      "status": "UNKNOWN",
      "last_update": "2022-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FORETINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00726323",
      "title": "A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)",
      "status": "COMPLETED",
      "last_update": "2017-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "FRUQUINTINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05522231",
      "title": "Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-03",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05831891",
      "title": "Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06317298",
      "title": "Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy",
      "status": "UNKNOWN",
      "last_update": "2024-03-19",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07488533",
      "title": "Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GIRENTUXIMAB": {
    "n": 18,
    "n_observational": 2,
    "n_active": 8,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05663710",
      "title": "Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment na\u00efve Patients With Advanced Clear Cell RCC",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05868174",
      "title": "Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447103",
      "title": "An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06750419",
      "title": "89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study",
      "status": "RECRUITING",
      "last_update": "2024-12-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07179770",
      "title": "Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07197580",
      "title": "Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00087022",
      "title": "Monoclonal Antibody Therapy (Rencarex\u00ae) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-11-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00717587",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01762592",
      "title": "REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT",
      "status": "WITHDRAWN",
      "last_update": "2017-12-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02002312",
      "title": "Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02497599",
      "title": "Intraoperative Dual-modality Imaging in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-09-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02883153",
      "title": "Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-06-19",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03556046",
      "title": "89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE",
      "status": "COMPLETED",
      "last_update": "2019-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03849118",
      "title": "89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study",
      "status": "COMPLETED",
      "last_update": "2024-05-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04496089",
      "title": "Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC",
      "status": "COMPLETED",
      "last_update": "2021-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239533",
      "title": "Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05861778",
      "title": "Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-12-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07077083",
      "title": "CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "INCB-086550": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04629339",
      "title": "Study of INCB086550 in Select Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IODINE I 124 GIRENTUXIMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00717587",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LENVATINIB": {
    "n": 55,
    "n_observational": 4,
    "n_active": 33,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04977453",
      "title": "GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024214",
      "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05319015",
      "title": "Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus",
      "status": "RECRUITING",
      "last_update": "2025-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05327686",
      "title": "Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial",
      "status": "RECRUITING",
      "last_update": "2026-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05733715",
      "title": "Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364631",
      "title": "CARE1 Pragmatic Clinical Trial",
      "status": "RECRUITING",
      "last_update": "2025-01-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06726421",
      "title": "Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06903312",
      "title": "Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.",
      "status": "RECRUITING",
      "last_update": "2025-07-03",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06962787",
      "title": "A Study of BL-B01D1+TKI\u00b1Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07097935",
      "title": "Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-08-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07383441",
      "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07389629",
      "title": "Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07571551",
      "title": "Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01136733",
      "title": "A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment",
      "status": "COMPLETED",
      "last_update": "2019-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02454478",
      "title": "Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2019-03-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02811861",
      "title": "Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02915783",
      "title": "A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease",
      "status": "COMPLETED",
      "last_update": "2023-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03006887",
      "title": "Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03173560",
      "title": "Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-04-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03324373",
      "title": "Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04203901",
      "title": "Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2023-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04267120",
      "title": "Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)",
      "status": "TERMINATED",
      "last_update": "2025-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04393350",
      "title": "Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04522323",
      "title": "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04586231",
      "title": "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626479",
      "title": "Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04626518",
      "title": "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04704219",
      "title": "Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)",
      "status": "COMPLETED",
      "last_update": "2025-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04714697",
      "title": "Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04736706",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04955743",
      "title": "Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2026-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05012371",
      "title": "Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05030506",
      "title": "A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05188118",
      "title": "Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-07-29",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05262413",
      "title": "A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)",
      "status": "UNKNOWN",
      "last_update": "2022-03-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05485883",
      "title": "Tislelizumab Plus Lenvatinib in Stage III-IV RCC",
      "status": "UNKNOWN",
      "last_update": "2022-08-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05485896",
      "title": "Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC",
      "status": "COMPLETED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05487859",
      "title": "Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620134",
      "title": "Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05877820",
      "title": "A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC",
      "status": "COMPLETED",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05899049",
      "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949424",
      "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06035224",
      "title": "Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06114940",
      "title": "Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)",
      "status": "TERMINATED",
      "last_update": "2026-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06129955",
      "title": "Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06138496",
      "title": "Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06574412",
      "title": "Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07011849",
      "title": "Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases",
      "status": "WITHDRAWN",
      "last_update": "2025-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07256223",
      "title": "A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07277972",
      "title": "Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07460206",
      "title": "Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07593040",
      "title": "Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07715565",
      "title": "Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07741617",
      "title": "A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LINIFANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00486538",
      "title": "Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NINGETINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03876925",
      "title": "A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC",
      "status": "TERMINATED",
      "last_update": "2021-03-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NINTEDANIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01024920",
      "title": "Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.",
      "status": "COMPLETED",
      "last_update": "2021-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278978",
      "title": "BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2015-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02835833",
      "title": "Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2018-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NINTEDANIB ESYLATE": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01024920",
      "title": "Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.",
      "status": "COMPLETED",
      "last_update": "2021-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278978",
      "title": "BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2015-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02835833",
      "title": "Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2018-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OMIPALISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ORANTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00024063",
      "title": "SU006668 in Treating Patients With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OSI-930": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00513851",
      "title": "Phase 1 Study of OSI-930 in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2011-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00603356",
      "title": "Phase I Study of OSI-930 and Erlotinib in Cancer Tumors",
      "status": "COMPLETED",
      "last_update": "2011-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PAZOPANIB": {
    "n": 82,
    "n_observational": 18,
    "n_active": 9,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03592472",
      "title": "A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)",
      "status": "RECRUITING",
      "last_update": "2025-04-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04823923",
      "title": "Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2025-02-12",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06726421",
      "title": "Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07087158",
      "title": "A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00158782",
      "title": "Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2017-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244764",
      "title": "GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00256880",
      "title": "Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma",
      "status": "COMPLETED",
      "last_update": "2017-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00334282",
      "title": "Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-02-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00363194",
      "title": "A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2017-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00387205",
      "title": "Study To Assess Long Term Safety Of Pazopanib",
      "status": "COMPLETED",
      "last_update": "2019-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00387764",
      "title": "Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2014-01-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00401583",
      "title": "A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes",
      "status": "COMPLETED",
      "last_update": "2017-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00471536",
      "title": "Pazopanib in Treating Patients With Metastatic Urothelial Cancer",
      "status": "COMPLETED",
      "last_update": "2014-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478725",
      "title": "Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034",
      "status": "COMPLETED",
      "last_update": "2017-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00516672",
      "title": "Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720941",
      "title": "Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00731211",
      "title": "Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00749320",
      "title": "Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2020-02-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00861029",
      "title": "VEG111485: A QTc Study of Pazopanib",
      "status": "COMPLETED",
      "last_update": "2017-11-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00992121",
      "title": "An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01012362",
      "title": "Study of Pazopanib and Ixabepilone in Patients With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01031875",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment",
      "status": "COMPLETED",
      "last_update": "2013-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01064310",
      "title": "Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01130623",
      "title": "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01147822",
      "title": "Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01157091",
      "title": "Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01158521",
      "title": "Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01184326",
      "title": "Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer",
      "status": "COMPLETED",
      "last_update": "2019-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01202032",
      "title": "Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2016-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01217931",
      "title": "Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01221506",
      "title": "Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2020-03-26",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01235962",
      "title": "A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2020-11-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01361113",
      "title": "Neoadjuvant Pazopanib in Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2018-04-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392183",
      "title": "Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2021-09-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01392352",
      "title": "HYPAZ: Hypertension Induced by Pazopanib",
      "status": "TERMINATED",
      "last_update": "2020-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01408004",
      "title": "Rotating Pazopanib and Everolimus to Avoid Resistance",
      "status": "COMPLETED",
      "last_update": "2014-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472081",
      "title": "Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",
      "status": "COMPLETED",
      "last_update": "2021-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01513187",
      "title": "Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2022-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01514448",
      "title": "Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib",
      "status": "COMPLETED",
      "last_update": "2017-07-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01521715",
      "title": "First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2017-08-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01538238",
      "title": "pazopanib_NCRCC,Ph2 STUDY",
      "status": "COMPLETED",
      "last_update": "2017-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01545817",
      "title": "Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01566747",
      "title": "Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5",
      "status": "COMPLETED",
      "last_update": "2021-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01575548",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01577784",
      "title": "Pazopanib in Second-line Therapy in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2014-03-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01582204",
      "title": "Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01599832",
      "title": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2017-06-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01613846",
      "title": "Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)",
      "status": "COMPLETED",
      "last_update": "2017-04-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01622660",
      "title": "Gemcitabine and Pazopanib in Chemotherapy Na\u00efve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy",
      "status": "TERMINATED",
      "last_update": "2017-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01664182",
      "title": "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01684397",
      "title": "Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01731158",
      "title": "Sequential Therapy in Metastatic Renal Cell Carinoma",
      "status": "COMPLETED",
      "last_update": "2019-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01767636",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01961583",
      "title": "[18F]Fluciclatide PET Imaging of Pazopanib Response",
      "status": "TERMINATED",
      "last_update": "2016-03-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02009449",
      "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02014636",
      "title": "Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)",
      "status": "COMPLETED",
      "last_update": "2020-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02089802",
      "title": "Optimizing Pazopanib Exposure in RCC Patients",
      "status": "TERMINATED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02122003",
      "title": "Second Line Sorafenib After Pazopanib in Patients With RCC",
      "status": "TERMINATED",
      "last_update": "2017-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02187302",
      "title": "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)",
      "status": "COMPLETED",
      "last_update": "2020-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02208128",
      "title": "Molecular Determinants for Therapy Response on Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2014-08-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02307474",
      "title": "A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer",
      "status": "WITHDRAWN",
      "last_update": "2016-03-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02324803",
      "title": "Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients",
      "status": "UNKNOWN",
      "last_update": "2014-12-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02406521",
      "title": "Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets",
      "status": "COMPLETED",
      "last_update": "2020-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535351",
      "title": "Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery",
      "status": "TERMINATED",
      "last_update": "2018-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02555748",
      "title": "Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02560012",
      "title": "Personalized Targeted Inhibitors Treatment in Renal Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02570789",
      "title": "Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy",
      "status": "TERMINATED",
      "last_update": "2021-03-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02729194",
      "title": "Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-06-10",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02795819",
      "title": "Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2019-10-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02956798",
      "title": "SAbR For Oligometastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959554",
      "title": "Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control",
      "status": "TERMINATED",
      "last_update": "2021-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02960906",
      "title": "A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Na\u00efve Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03062410",
      "title": "Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-07-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03200717",
      "title": "Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment",
      "status": "COMPLETED",
      "last_update": "2023-08-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03260894",
      "title": "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)",
      "status": "COMPLETED",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03334409",
      "title": "Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2022-03-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03379012",
      "title": "Testosterone in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2019-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571438",
      "title": "Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-01-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04462445",
      "title": "Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb",
      "status": "COMPLETED",
      "last_update": "2020-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05816642",
      "title": "Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949424",
      "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RAMUCIRUMAB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00515697",
      "title": "A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01282463",
      "title": "Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01772004",
      "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)",
      "status": "COMPLETED",
      "last_update": "2021-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02082210",
      "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02426125",
      "title": "A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer",
      "status": "COMPLETED",
      "last_update": "2023-08-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02443324",
      "title": "A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03798626",
      "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",
      "status": "COMPLETED",
      "last_update": "2026-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03872947",
      "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 7,
    "n_observational": 1,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "status": "RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00664326",
      "title": "A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC",
      "status": "COMPLETED",
      "last_update": "2021-01-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01853046",
      "title": "Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment",
      "status": "COMPLETED",
      "last_update": "2017-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02085148",
      "title": "A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy",
      "status": "COMPLETED",
      "last_update": "2024-04-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02459119",
      "title": "Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)",
      "status": "COMPLETED",
      "last_update": "2020-08-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03475953",
      "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-03-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03890731",
      "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed",
      "status": "COMPLETED",
      "last_update": "2024-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SAMOTOLISIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03155620",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03213678",
      "title": "Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)",
      "status": "COMPLETED",
      "last_update": "2026-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SAPANISERTIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02724020",
      "title": "MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2021-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03097328",
      "title": "Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SAVOLITINIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02127710",
      "title": "A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)",
      "status": "COMPLETED",
      "last_update": "2021-04-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02761057",
      "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02819596",
      "title": "MEDI4736 Combinations in Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2024-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03091192",
      "title": "Savolitinib vs. Sunitinib in MET-driven PRCC.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05043090",
      "title": "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SEMAXANIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00006384",
      "title": "SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2011-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00009919",
      "title": "SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment",
      "status": "TERMINATED",
      "last_update": "2013-01-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SORAFENIB": {
    "n": 89,
    "n_observational": 31,
    "n_active": 1,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT06690697",
      "title": "Combination of Toripalimab and JS004 Therapy for ccRCC",
      "status": "RECRUITING",
      "last_update": "2024-11-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073307",
      "title": "Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2014-02-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00079612",
      "title": "Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer",
      "status": "COMPLETED",
      "last_update": "2014-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00098618",
      "title": "Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2013-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101114",
      "title": "Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110344",
      "title": "Research Study for Patients With Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2013-10-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00111020",
      "title": "Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00112671",
      "title": "Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract",
      "status": "COMPLETED",
      "last_update": "2018-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00112905",
      "title": "Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium",
      "status": "TERMINATED",
      "last_update": "2014-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00117637",
      "title": "BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00118170",
      "title": "Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function",
      "status": "COMPLETED",
      "last_update": "2013-01-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00121251",
      "title": "Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00126503",
      "title": "Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2015-01-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00126594",
      "title": "Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2016-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00126659",
      "title": "Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2018-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00301847",
      "title": "Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00326898",
      "title": "Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00352859",
      "title": "Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib",
      "status": "TERMINATED",
      "last_update": "2014-12-30",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00378703",
      "title": "Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-11-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00384969",
      "title": "Sorafenib and RAD001 Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-08-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00389285",
      "title": "Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2009-05-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00392821",
      "title": "Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398814",
      "title": "Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2014-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00405366",
      "title": "Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00410124",
      "title": "RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00418496",
      "title": "Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma",
      "status": "COMPLETED",
      "last_update": "2017-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00445042",
      "title": "Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2016-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00448149",
      "title": "Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2016-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00467025",
      "title": "AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib",
      "status": "COMPLETED",
      "last_update": "2016-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00474786",
      "title": "Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-11-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478114",
      "title": "Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2011-08-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00480389",
      "title": "Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal",
      "status": "COMPLETED",
      "last_update": "2015-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00492258",
      "title": "Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2013-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00492986",
      "title": "An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-12-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496301",
      "title": "Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC",
      "status": "COMPLETED",
      "last_update": "2009-01-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496756",
      "title": "Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2023-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00498966",
      "title": "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney",
      "status": "COMPLETED",
      "last_update": "2018-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00557830",
      "title": "Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2013-07-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00586105",
      "title": "Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2014-04-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00586495",
      "title": "Long-term Extension From RCC Phase II (11515)",
      "status": "COMPLETED",
      "last_update": "2013-12-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00589550",
      "title": "PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2015-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00602862",
      "title": "Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250",
      "status": "COMPLETED",
      "last_update": "2013-12-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00606866",
      "title": "MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2023-11-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00609401",
      "title": "Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2009-02-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00609934",
      "title": "Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone",
      "status": "COMPLETED",
      "last_update": "2015-07-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00618982",
      "title": "Sorafenib Dose Escalation in Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-12-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00622479",
      "title": "Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.",
      "status": "TERMINATED",
      "last_update": "2014-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00635791",
      "title": "Phase I Study of Vorinostat and Sorafenib in Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00661375",
      "title": "BAY43-9006 Phase II Study for Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-12-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00672178",
      "title": "Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)",
      "status": "TERMINATED",
      "last_update": "2017-01-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678288",
      "title": "A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.",
      "status": "TERMINATED",
      "last_update": "2014-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678392",
      "title": "Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2019-01-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00727532",
      "title": "Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2019-05-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00732914",
      "title": "Sequential Study to Treat Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-04-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00827177",
      "title": "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00848640",
      "title": "Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00854620",
      "title": "Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2015-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00866320",
      "title": "Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2014-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00920816",
      "title": "Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2022-05-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01005797",
      "title": "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",
      "status": "COMPLETED",
      "last_update": "2017-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030783",
      "title": "A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-10-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01041482",
      "title": "A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2010-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01076010",
      "title": "An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).",
      "status": "COMPLETED",
      "last_update": "2020-10-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01100242",
      "title": "Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01178411",
      "title": "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols",
      "status": "COMPLETED",
      "last_update": "2021-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01183663",
      "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",
      "status": "COMPLETED",
      "last_update": "2016-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01189370",
      "title": "Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2017-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01223027",
      "title": "Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-12-07",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01246817",
      "title": "Temsirolimus-RCC-imaging",
      "status": "UNKNOWN",
      "last_update": "2012-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01342627",
      "title": "Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01441388",
      "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.",
      "status": "WITHDRAWN",
      "last_update": "2011-12-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01444807",
      "title": "Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases",
      "status": "UNKNOWN",
      "last_update": "2021-09-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01481870",
      "title": "Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2013-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01497444",
      "title": "Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2020-02-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01502410",
      "title": "Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",
      "status": "COMPLETED",
      "last_update": "2018-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01582009",
      "title": "Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate",
      "status": "TERMINATED",
      "last_update": "2022-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01613846",
      "title": "Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)",
      "status": "COMPLETED",
      "last_update": "2017-04-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01616186",
      "title": "Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2013-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01664182",
      "title": "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01731158",
      "title": "Sequential Therapy in Metastatic Renal Cell Carinoma",
      "status": "COMPLETED",
      "last_update": "2019-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01762150",
      "title": "Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma",
      "status": "COMPLETED",
      "last_update": "2018-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01844947",
      "title": "Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract",
      "status": "COMPLETED",
      "last_update": "2019-04-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02122003",
      "title": "Second Line Sorafenib After Pazopanib in Patients With RCC",
      "status": "TERMINATED",
      "last_update": "2017-11-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02187302",
      "title": "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)",
      "status": "COMPLETED",
      "last_update": "2020-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02330783",
      "title": "Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients",
      "status": "UNKNOWN",
      "last_update": "2017-05-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02406521",
      "title": "Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets",
      "status": "COMPLETED",
      "last_update": "2020-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02560012",
      "title": "Personalized Targeted Inhibitors Treatment in Renal Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02627963",
      "title": "A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2023-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03456401",
      "title": "Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)",
      "status": "TERMINATED",
      "last_update": "2018-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB": {
    "n": 152,
    "n_observational": 48,
    "n_active": 13,
    "n_withdrawn": 5,
    "trials": [
     {
      "nct": "NCT06222593",
      "title": "Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06726421",
      "title": "Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054886",
      "title": "Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2007-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089648",
      "title": "SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-01-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00113529",
      "title": "Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00137423",
      "title": "Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2009-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254540",
      "title": "Study of SU011248 in Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2010-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00267748",
      "title": "Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)",
      "status": "COMPLETED",
      "last_update": "2011-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00326898",
      "title": "Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00338884",
      "title": "Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2012-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00372853",
      "title": "Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2012-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00375674",
      "title": "A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397488",
      "title": "Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium",
      "status": "COMPLETED",
      "last_update": "2016-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00399152",
      "title": "Perifosine + Sunitinib Malate for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2014-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00410124",
      "title": "RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00417677",
      "title": "A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2007-12-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00421512",
      "title": "A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2008-11-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00422344",
      "title": "A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-02-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00444314",
      "title": "Phase 2 Study of Panzem\u00ae NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00459875",
      "title": "Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2015-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00462982",
      "title": "Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00465179",
      "title": "Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00474786",
      "title": "Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-11-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00480935",
      "title": "A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00486538",
      "title": "Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00491738",
      "title": "A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)",
      "status": "TERMINATED",
      "last_update": "2009-04-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00498966",
      "title": "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney",
      "status": "COMPLETED",
      "last_update": "2018-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00499135",
      "title": "Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00520533",
      "title": "Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00522249",
      "title": "Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC",
      "status": "TERMINATED",
      "last_update": "2016-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00531544",
      "title": "A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248",
      "status": "COMPLETED",
      "last_update": "2016-01-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00541008",
      "title": "Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556049",
      "title": "Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556205",
      "title": "Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2016-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00570882",
      "title": "Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2014-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00619268",
      "title": "Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2013-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00663559",
      "title": "Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy",
      "status": "COMPLETED",
      "last_update": "2014-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678119",
      "title": "Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment",
      "status": "COMPLETED",
      "last_update": "2013-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678288",
      "title": "A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.",
      "status": "TERMINATED",
      "last_update": "2014-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00694096",
      "title": "Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response",
      "status": "COMPLETED",
      "last_update": "2015-12-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00706706",
      "title": "Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00709995",
      "title": "A Study for Participants With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00715442",
      "title": "Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00717587",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720941",
      "title": "Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00731211",
      "title": "Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00732914",
      "title": "Sequential Study to Treat Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-04-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00747305",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery",
      "status": "TERMINATED",
      "last_update": "2015-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00749320",
      "title": "Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2020-02-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00788060",
      "title": "A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00792025",
      "title": "Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00814021",
      "title": "Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain",
      "status": "COMPLETED",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00849186",
      "title": "Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2015-02-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00853125",
      "title": "Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2021-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00853372",
      "title": "AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2020-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00866320",
      "title": "Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2014-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00869011",
      "title": "Exercise for Patients With Renal Cell Cancer Receiving Sunitinib",
      "status": "UNKNOWN",
      "last_update": "2009-12-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00890110",
      "title": "Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib",
      "status": "UNKNOWN",
      "last_update": "2009-04-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00891475",
      "title": "Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2014-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00903175",
      "title": "Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00930033",
      "title": "Clinical Trial to Assess the Importance of Nephrectomy",
      "status": "COMPLETED",
      "last_update": "2025-09-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00930345",
      "title": "Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-04-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00943839",
      "title": "Sunitinib Malate in Treating Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2016-11-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00953446",
      "title": "Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2020-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00975806",
      "title": "Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00979966",
      "title": "Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib",
      "status": "COMPLETED",
      "last_update": "2012-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982657",
      "title": "A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01024205",
      "title": "Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2013-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01024920",
      "title": "Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.",
      "status": "COMPLETED",
      "last_update": "2021-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01034878",
      "title": "Sunitinib in Metastatic Renal Cancer",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01061411",
      "title": "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01064310",
      "title": "Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01069770",
      "title": "Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)",
      "status": "UNKNOWN",
      "last_update": "2011-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01070186",
      "title": "Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2012-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01089088",
      "title": "Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)",
      "status": "COMPLETED",
      "last_update": "2018-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01099423",
      "title": "Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108445",
      "title": "Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2018-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01118039",
      "title": "Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01158222",
      "title": "Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164228",
      "title": "Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216371",
      "title": "Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)",
      "status": "TERMINATED",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01219751",
      "title": "Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2011-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01258348",
      "title": "A Phase 1b Trial in Patients With Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01402089",
      "title": "Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2016-02-02",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472081",
      "title": "Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",
      "status": "COMPLETED",
      "last_update": "2021-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01481870",
      "title": "Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2013-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01482949",
      "title": "A Rollover Protocol for Subjects Previously Treated With AGS-003",
      "status": "TERMINATED",
      "last_update": "2018-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01502228",
      "title": "PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-03-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01514448",
      "title": "Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib",
      "status": "COMPLETED",
      "last_update": "2017-07-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01517243",
      "title": "Phase II Study of Alternating Sunitinib and Temsirolimus",
      "status": "COMPLETED",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01566747",
      "title": "Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5",
      "status": "COMPLETED",
      "last_update": "2021-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01582009",
      "title": "Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate",
      "status": "TERMINATED",
      "last_update": "2022-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01616186",
      "title": "Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2013-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01664182",
      "title": "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01673386",
      "title": "A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC",
      "status": "TERMINATED",
      "last_update": "2020-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01731158",
      "title": "Sequential Therapy in Metastatic Renal Cell Carinoma",
      "status": "COMPLETED",
      "last_update": "2019-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01740154",
      "title": "Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2018-12-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01743300",
      "title": "The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2012-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01784978",
      "title": "Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer",
      "status": "TERMINATED",
      "last_update": "2017-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01835158",
      "title": "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01984242",
      "title": "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin\u00ae) Compared to Sunitinib (Sutent\u00ae) in Participants With Untreated Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02019576",
      "title": "Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2021-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02060370",
      "title": "Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2020-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02071641",
      "title": "Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2017-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02072031",
      "title": "Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma\uff08RCC\uff09",
      "status": "UNKNOWN",
      "last_update": "2016-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02208128",
      "title": "Molecular Determinants for Therapy Response on Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2014-08-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02231749",
      "title": "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02324803",
      "title": "Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients",
      "status": "UNKNOWN",
      "last_update": "2014-12-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02386111",
      "title": "A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2018-07-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420821",
      "title": "A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2023-01-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02432846",
      "title": "Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2022-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02446795",
      "title": "Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial",
      "status": "UNKNOWN",
      "last_update": "2017-01-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535351",
      "title": "Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery",
      "status": "TERMINATED",
      "last_update": "2018-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02555748",
      "title": "Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02560012",
      "title": "Personalized Targeted Inhibitors Treatment in Renal Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02570789",
      "title": "Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy",
      "status": "TERMINATED",
      "last_update": "2021-03-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626754",
      "title": "A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population",
      "status": "TERMINATED",
      "last_update": "2018-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02684006",
      "title": "A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02688491",
      "title": "A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment",
      "status": "UNKNOWN",
      "last_update": "2016-02-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02689167",
      "title": "Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02761057",
      "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02811861",
      "title": "Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853331",
      "title": "Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)",
      "status": "COMPLETED",
      "last_update": "2026-02-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959554",
      "title": "Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control",
      "status": "TERMINATED",
      "last_update": "2021-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02960906",
      "title": "A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Na\u00efve Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013946",
      "title": "Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy",
      "status": "TERMINATED",
      "last_update": "2025-02-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03035630",
      "title": "Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2022-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03062410",
      "title": "Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-07-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03066427",
      "title": "Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.",
      "status": "COMPLETED",
      "last_update": "2020-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03091192",
      "title": "Savolitinib vs. Sunitinib in MET-driven PRCC.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03109015",
      "title": "Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing",
      "status": "COMPLETED",
      "last_update": "2024-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03141177",
      "title": "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03260894",
      "title": "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)",
      "status": "COMPLETED",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03323710",
      "title": "Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2019-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03379012",
      "title": "Testosterone in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2019-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03456401",
      "title": "Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)",
      "status": "TERMINATED",
      "last_update": "2018-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03541902",
      "title": "Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571438",
      "title": "Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-01-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03592199",
      "title": "Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib",
      "status": "UNKNOWN",
      "last_update": "2019-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03729245",
      "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)",
      "status": "TERMINATED",
      "last_update": "2023-04-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03905889",
      "title": "A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04394975",
      "title": "Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2025-11-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04523272",
      "title": "A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05043090",
      "title": "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05678673",
      "title": "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800106",
      "title": "A Bioequivalence Study of Sunitinib Malate Capsules.",
      "status": "COMPLETED",
      "last_update": "2023-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05816642",
      "title": "Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949424",
      "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06032728",
      "title": "Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390826",
      "title": "Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07165418",
      "title": "A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB MALATE": {
    "n": 154,
    "n_observational": 46,
    "n_active": 14,
    "n_withdrawn": 5,
    "trials": [
     {
      "nct": "NCT06222593",
      "title": "Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC",
      "status": "RECRUITING",
      "last_update": "2026-04-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06726421",
      "title": "Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)",
      "status": "RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089648",
      "title": "SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-01-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00113529",
      "title": "Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-08-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00137423",
      "title": "Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2009-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00254540",
      "title": "Study of SU011248 in Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2010-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00267748",
      "title": "Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)",
      "status": "COMPLETED",
      "last_update": "2011-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00326898",
      "title": "Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2026-06-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00338884",
      "title": "Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2012-08-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00372853",
      "title": "Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2012-06-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00375674",
      "title": "A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397488",
      "title": "Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium",
      "status": "COMPLETED",
      "last_update": "2016-01-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00399152",
      "title": "Perifosine + Sunitinib Malate for Patients With Advanced Cancers",
      "status": "COMPLETED",
      "last_update": "2014-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00410124",
      "title": "RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-01-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00417677",
      "title": "A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2007-12-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00421512",
      "title": "A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2008-11-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00422344",
      "title": "A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2010-02-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00444314",
      "title": "Phase 2 Study of Panzem\u00ae NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00459875",
      "title": "Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2015-11-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00462982",
      "title": "Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma",
      "status": "COMPLETED",
      "last_update": "2015-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00465179",
      "title": "Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00474786",
      "title": "Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-11-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00480935",
      "title": "A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00486538",
      "title": "Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2013-01-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00491738",
      "title": "A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)",
      "status": "TERMINATED",
      "last_update": "2009-04-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00498966",
      "title": "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney",
      "status": "COMPLETED",
      "last_update": "2018-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00499135",
      "title": "Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00520533",
      "title": "Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2022-10-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00522249",
      "title": "Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC",
      "status": "TERMINATED",
      "last_update": "2016-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00531544",
      "title": "A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248",
      "status": "COMPLETED",
      "last_update": "2016-01-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00541008",
      "title": "Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556049",
      "title": "Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556205",
      "title": "Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2016-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00570882",
      "title": "Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2014-09-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00619268",
      "title": "Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2013-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00663559",
      "title": "Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy",
      "status": "COMPLETED",
      "last_update": "2014-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678119",
      "title": "Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment",
      "status": "COMPLETED",
      "last_update": "2013-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00678288",
      "title": "A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.",
      "status": "TERMINATED",
      "last_update": "2014-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00694096",
      "title": "Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response",
      "status": "COMPLETED",
      "last_update": "2015-12-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00706706",
      "title": "Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2013-01-18",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00709995",
      "title": "A Study for Participants With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-09-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00715442",
      "title": "Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00717587",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2014-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720941",
      "title": "Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00731211",
      "title": "Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00732914",
      "title": "Sequential Study to Treat Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2014-04-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00747305",
      "title": "Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery",
      "status": "TERMINATED",
      "last_update": "2015-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00749320",
      "title": "Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2020-02-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00788060",
      "title": "A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00792025",
      "title": "Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2011-05-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00814021",
      "title": "Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain",
      "status": "COMPLETED",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00849186",
      "title": "Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2015-02-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00853125",
      "title": "Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2021-04-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00853372",
      "title": "AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2020-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00866320",
      "title": "Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab",
      "status": "COMPLETED",
      "last_update": "2014-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00869011",
      "title": "Exercise for Patients With Renal Cell Cancer Receiving Sunitinib",
      "status": "UNKNOWN",
      "last_update": "2009-12-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00890110",
      "title": "Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib",
      "status": "UNKNOWN",
      "last_update": "2009-04-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00891475",
      "title": "Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2014-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00903175",
      "title": "Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-11-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00930033",
      "title": "Clinical Trial to Assess the Importance of Nephrectomy",
      "status": "COMPLETED",
      "last_update": "2025-09-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00930345",
      "title": "Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-04-01",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00943839",
      "title": "Sunitinib Malate in Treating Patients With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2016-11-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00953446",
      "title": "Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2020-06-30",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00975806",
      "title": "Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00979966",
      "title": "Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib",
      "status": "COMPLETED",
      "last_update": "2012-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00982657",
      "title": "A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2015-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01024205",
      "title": "Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2013-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01024920",
      "title": "Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.",
      "status": "COMPLETED",
      "last_update": "2021-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01034878",
      "title": "Sunitinib in Metastatic Renal Cancer",
      "status": "COMPLETED",
      "last_update": "2014-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01061411",
      "title": "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2022-08-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01064310",
      "title": "Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01069770",
      "title": "Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)",
      "status": "UNKNOWN",
      "last_update": "2011-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01070186",
      "title": "Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2012-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01089088",
      "title": "Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)",
      "status": "COMPLETED",
      "last_update": "2018-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01099423",
      "title": "Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108445",
      "title": "Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2018-01-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01118039",
      "title": "Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer",
      "status": "UNKNOWN",
      "last_update": "2013-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01122615",
      "title": "Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)",
      "status": "COMPLETED",
      "last_update": "2015-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01158222",
      "title": "Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-09-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01164228",
      "title": "Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01216371",
      "title": "Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)",
      "status": "TERMINATED",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01219751",
      "title": "Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2011-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01258348",
      "title": "A Phase 1b Trial in Patients With Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01402089",
      "title": "Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2016-02-02",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01472081",
      "title": "Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",
      "status": "COMPLETED",
      "last_update": "2021-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01481870",
      "title": "Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2013-02-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01482949",
      "title": "A Rollover Protocol for Subjects Previously Treated With AGS-003",
      "status": "TERMINATED",
      "last_update": "2018-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01502228",
      "title": "PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2019-03-05",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01514448",
      "title": "Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib",
      "status": "COMPLETED",
      "last_update": "2017-07-19",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01517243",
      "title": "Phase II Study of Alternating Sunitinib and Temsirolimus",
      "status": "COMPLETED",
      "last_update": "2023-09-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01566747",
      "title": "Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5",
      "status": "COMPLETED",
      "last_update": "2021-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01582009",
      "title": "Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate",
      "status": "TERMINATED",
      "last_update": "2022-08-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01582204",
      "title": "Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01616186",
      "title": "Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)",
      "status": "WITHDRAWN",
      "last_update": "2013-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01664182",
      "title": "Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01673386",
      "title": "A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC",
      "status": "TERMINATED",
      "last_update": "2020-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01731158",
      "title": "Sequential Therapy in Metastatic Renal Cell Carinoma",
      "status": "COMPLETED",
      "last_update": "2019-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01740154",
      "title": "Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2018-12-06",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01743300",
      "title": "The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2012-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01784978",
      "title": "Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer",
      "status": "TERMINATED",
      "last_update": "2017-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01835158",
      "title": "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01984242",
      "title": "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin\u00ae) Compared to Sunitinib (Sutent\u00ae) in Participants With Untreated Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02019576",
      "title": "Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib",
      "status": "COMPLETED",
      "last_update": "2021-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02060370",
      "title": "Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2020-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02071641",
      "title": "Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2017-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02072031",
      "title": "Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma\uff08RCC\uff09",
      "status": "UNKNOWN",
      "last_update": "2016-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02208128",
      "title": "Molecular Determinants for Therapy Response on Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2014-08-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02231749",
      "title": "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)",
      "status": "COMPLETED",
      "last_update": "2026-05-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02324803",
      "title": "Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients",
      "status": "UNKNOWN",
      "last_update": "2014-12-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02386111",
      "title": "A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2018-07-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02398552",
      "title": "A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.",
      "status": "UNKNOWN",
      "last_update": "2016-03-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02420821",
      "title": "A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2023-01-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02432846",
      "title": "Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)",
      "status": "COMPLETED",
      "last_update": "2022-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02446795",
      "title": "Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial",
      "status": "UNKNOWN",
      "last_update": "2017-01-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02535351",
      "title": "Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery",
      "status": "TERMINATED",
      "last_update": "2018-11-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02555748",
      "title": "Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-03-31",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02560012",
      "title": "Personalized Targeted Inhibitors Treatment in Renal Cell Cancer",
      "status": "TERMINATED",
      "last_update": "2018-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02570789",
      "title": "Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy",
      "status": "TERMINATED",
      "last_update": "2021-03-23",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02626754",
      "title": "A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population",
      "status": "TERMINATED",
      "last_update": "2018-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02684006",
      "title": "A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)",
      "status": "COMPLETED",
      "last_update": "2025-07-30",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02688491",
      "title": "A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment",
      "status": "UNKNOWN",
      "last_update": "2016-02-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02689167",
      "title": "Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-11-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02761057",
      "title": "Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed",
      "status": "COMPLETED",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02811861",
      "title": "Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853331",
      "title": "Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)",
      "status": "COMPLETED",
      "last_update": "2026-02-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959554",
      "title": "Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control",
      "status": "TERMINATED",
      "last_update": "2021-09-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02960906",
      "title": "A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Na\u00efve Metastatic Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03013946",
      "title": "Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy",
      "status": "TERMINATED",
      "last_update": "2025-02-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03035630",
      "title": "Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2022-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03062410",
      "title": "Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-07-26",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03066427",
      "title": "Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.",
      "status": "COMPLETED",
      "last_update": "2020-11-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03091192",
      "title": "Savolitinib vs. Sunitinib in MET-driven PRCC.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03109015",
      "title": "Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing",
      "status": "COMPLETED",
      "last_update": "2024-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03141177",
      "title": "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-08-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03260894",
      "title": "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)",
      "status": "COMPLETED",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03323710",
      "title": "Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma",
      "status": "WITHDRAWN",
      "last_update": "2019-01-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03379012",
      "title": "Testosterone in Metastatic Renal Cell Carcinoma Patients",
      "status": "COMPLETED",
      "last_update": "2019-10-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03456401",
      "title": "Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)",
      "status": "TERMINATED",
      "last_update": "2018-03-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03541902",
      "title": "Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571438",
      "title": "Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-01-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03592199",
      "title": "Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib",
      "status": "UNKNOWN",
      "last_update": "2019-09-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03729245",
      "title": "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)",
      "status": "TERMINATED",
      "last_update": "2023-04-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03905889",
      "title": "A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04394975",
      "title": "Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2025-11-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04523272",
      "title": "A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05043090",
      "title": "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05678673",
      "title": "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05800106",
      "title": "A Bioequivalence Study of Sunitinib Malate Capsules.",
      "status": "COMPLETED",
      "last_update": "2023-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05816642",
      "title": "Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2023-04-18",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05949424",
      "title": "OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults",
      "status": "UNKNOWN",
      "last_update": "2023-11-29",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06032728",
      "title": "Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-09-13",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390826",
      "title": "Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07165418",
      "title": "A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TIVANTINIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00557609",
      "title": "Phase 2 Study in Patients With MiT Tumors",
      "status": "COMPLETED",
      "last_update": "2013-02-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00827177",
      "title": "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01178411",
      "title": "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols",
      "status": "COMPLETED",
      "last_update": "2021-03-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01447914",
      "title": "Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma",
      "status": "COMPLETED",
      "last_update": "2019-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01688973",
      "title": "Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2019-01-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TIVOZANIB": {
    "n": 15,
    "n_observational": 2,
    "n_active": 4,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05700461",
      "title": "Drug Screening Using Novel IMD in Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06053658",
      "title": "Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06661720",
      "title": "Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00502307",
      "title": "A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00563147",
      "title": "A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2011-10-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01030783",
      "title": "A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2019-10-28",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01076010",
      "title": "An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).",
      "status": "COMPLETED",
      "last_update": "2020-10-05",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01297244",
      "title": "A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2020-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01673386",
      "title": "A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC",
      "status": "TERMINATED",
      "last_update": "2020-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01769885",
      "title": "Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer",
      "status": "WITHDRAWN",
      "last_update": "2022-08-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01834183",
      "title": "Tivozanib + Gemcitabine in Metastatic RCC",
      "status": "WITHDRAWN",
      "last_update": "2013-06-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02627963",
      "title": "A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)",
      "status": "COMPLETED",
      "last_update": "2023-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136627",
      "title": "Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC",
      "status": "COMPLETED",
      "last_update": "2021-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04987203",
      "title": "Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma",
      "status": "COMPLETED",
      "last_update": "2026-05-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07218692",
      "title": "RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VANDETANIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00566995",
      "title": "Phase II Study of Vandetanib in Individuals With Kidney Cancer",
      "status": "COMPLETED",
      "last_update": "2018-10-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01191892",
      "title": "Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2019-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01372813",
      "title": "Vandetanib to Treat Advanced Kidney Cancer",
      "status": "TERMINATED",
      "last_update": "2015-10-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02495103",
      "title": "Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2021-01-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VATALANIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00303732",
      "title": "Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2016-03-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00655655",
      "title": "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VISTUSERTIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01793636",
      "title": "A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer",
      "status": "TERMINATED",
      "last_update": "2014-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "X-82": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02577458",
      "title": "Study of the Combination of CM082 With Everolimus in Patients With mRCC",
      "status": "UNKNOWN",
      "last_update": "2018-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03095040",
      "title": "CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2021-02-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "XL-999": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00277316",
      "title": "Study of XL999 in Patients With Metastatic Renal Cell Carcinoma",
      "status": "TERMINATED",
      "last_update": "2010-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}